Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 520 articles:
HTML format



Single Articles


    December 2022
  1. MORENO V, Sepulveda JM, Reardon DA, Perez-Nunez A, et al
    Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.
    Neuro Oncol. 2022 Dec 1:noac263. doi: 10.1093.
    PubMed     Abstract available


  2. WANG C, Zhang H, Fan J, Li Q, et al
    Inhibition of integrated stress response protects against lipid-induced senescence in hypothalamic neural stem cells in adamantinomatous craniopharyngioma.
    Neuro Oncol. 2022 Dec 1:noac261. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  3. GONZALEZ CASTRO LN, Liu I, Filbin M
    Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
    Neuro Oncol. 2022 Nov 29:noac257. doi: 10.1093.
    PubMed    


  4. PRINS RM, Everson RG
    Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.".
    Neuro Oncol. 2022 Nov 29:noac256. doi: 10.1093.
    PubMed    


  5. GERRITSEN JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, et al
    Impact of maximal extent of resection on postoperative deficits, patient functioning and survival within clinically important glioblastoma subgroups.
    Neuro Oncol. 2022 Nov 24:noac255. doi: 10.1093.
    PubMed     Abstract available


  6. LIN B, Ziebro J, Smithberger E, Skinner KR, et al
    Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma.
    Neuro Oncol. 2022 Nov 23:noac254. doi: 10.1093.
    PubMed    


  7. DEAN JA, Tanguturi SK, Cagney D, Shin KY, et al
    Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.
    Neuro Oncol. 2022 Nov 19:noac253. doi: 10.1093.
    PubMed     Abstract available


  8. ZHANG IY, Liu S, Zhang L, Liang R, et al
    RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression.
    Neuro Oncol. 2022 Nov 17. pii: 6832182. doi: 10.1093.
    PubMed     Abstract available


  9. FORRY S, Hubbard L, Espey MG, Vikram B, et al
    The NCI Glioblastoma Therapeutics Network (GTN).
    Neuro Oncol. 2022 Nov 11. pii: 6822421. doi: 10.1093.
    PubMed    


  10. GIRARDI F, Matz M, Stiller C, You H, et al
    Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).
    Neuro Oncol. 2022 Nov 10. pii: 6819785. doi: 10.1093.
    PubMed     Abstract available



  11. Corrigendum to: Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Nov 8. pii: 6809298. doi: 10.1093.
    PubMed    


  12. CHEN L, Xie X, Wang T, Xu L, et al
    ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.
    Neuro Oncol. 2022 Nov 2. pii: 6794117. doi: 10.1093.
    PubMed     Abstract available


  13. SMITH K, Nakaji P, Thomas T, Pinnaduwage D, et al
    Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  14. MCCRACKEN DJ, Schupper AJ, Lakomkin N, Malcolm J, et al
    Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  15. ODIA Y, Gutierrez AN, Kotecha R
    Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  16. SCHUPPER AJ, Chanenchuk T, Racanelli A, Price G, et al
    Laser hyperthermia: Past, present, and future.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  17. WU A, Wu JY, Lim M
    Updates in intraoperative strategies for enhancing intra-axial brain tumor control.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  18. HADDAD AF, Aghi MK, Butowski N
    Novel intraoperative strategies for enhancing tumor control: Future directions.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  19. HOOGENDIJK R, van der Lugt J, Hoving E, Kremer L, et al
    The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System: Implications for cancer registries.
    Neuro Oncol. 2022;24:1811-1814.
    PubMed    


  20. GALLDIKS N, Langen KJ, Albert NL, Law I, et al
    Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.
    Neuro Oncol. 2022;24:1815-1826.
    PubMed     Abstract available


  21. YEO KK, MacDonald SM
    CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past.
    Neuro Oncol. 2022;24:1962-1963.
    PubMed    


  22. FONSECA A, Faure-Conter C, Murray MJ, Fangusaro J, et al
    Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
    Neuro Oncol. 2022;24:1950-1961.
    PubMed     Abstract available


    October 2022
  23. NAKATA S, Murai J, Okada M, Takahashi H, et al
    Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.
    Neuro Oncol. 2022 Oct 23. pii: 6770101. doi: 10.1093.
    PubMed     Abstract available


  24. ZHAO J, Yang S, Cui X, Wang Q, et al
    A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Neuro Oncol. 2022 Oct 22. pii: 6770036. doi: 10.1093.
    PubMed     Abstract available


  25. KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
    Palliative care and end-of-life care in adults with malignant brain tumors.
    Neuro Oncol. 2022 Oct 22. pii: 6769915. doi: 10.1093.
    PubMed     Abstract available


  26. SHORT SC
    EV packing allows meningioma tracking in blood.
    Neuro Oncol. 2022 Oct 21. pii: 6765271. doi: 10.1093.
    PubMed    


  27. RUDA R
    Optimize Treatment Approaches In Isocitrate Dehydrogenase (Idh) Mutant Gliomas: Open Issues.
    Neuro Oncol. 2022 Oct 17. pii: 6761819. doi: 10.1093.
    PubMed    


  28. CHANG G, Xie GS, Ma L, Li P, et al
    USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
    Neuro Oncol. 2022 Oct 14. pii: 6761025. doi: 10.1093.
    PubMed     Abstract available


  29. GREEN K, Panagopoulou P, D'Arco F, O'Hare P, et al
    A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes.
    Neuro Oncol. 2022 Oct 14. pii: 6761018. doi: 10.1093.
    PubMed     Abstract available


  30. AWADA H, Paris F, Pecqueur C
    Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome.
    Neuro Oncol. 2022 Oct 14. pii: 6761020. doi: 10.1093.
    PubMed     Abstract available


  31. CHOUDHURY A, Chen WC, Lucas CG, Bayley JC, et al
    Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.
    Neuro Oncol. 2022 Oct 13. pii: 6760303. doi: 10.1093.
    PubMed     Abstract available


  32. MILLER JJ, Gonzalez Castro LN, McBrayer S, Weller M, et al
    Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
    Neuro Oncol. 2022 Oct 12. pii: 6761148. doi: 10.1093.
    PubMed     Abstract available


  33. KOROVINA I, Vehlow A, Temme A, Cordes N, et al
    Targeting integrin alpha2 as potential strategy for radiochemosensitization of glioblastoma.
    Neuro Oncol. 2022 Oct 11. pii: 6758417. doi: 10.1093.
    PubMed     Abstract available


  34. SCHAKELAAR MY, Monnikhof M, Crnko S, Pijnappel E, et al
    Cellular Immunotherapy for Medulloblastoma.
    Neuro Oncol. 2022 Oct 11. pii: 6758415. doi: 10.1093.
    PubMed     Abstract available


  35. WOLLRING MM, Werner JM, Bauer EK, Tscherpel C, et al
    Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Neuro Oncol. 2022 Oct 10. pii: 6755441. doi: 10.1093.
    PubMed     Abstract available


  36. YANG R, Zhang G, Dong Z, Wang S, et al
    HOXA3 and KDM6A cooperate in transcriptional control of aerobic glycolysis and glioblastoma progression.
    Neuro Oncol. 2022 Oct 10. pii: 6755443. doi: 10.1093.
    PubMed     Abstract available


  37. GIRARDI F, Di Carlo V, Stiller C, Gatta G, et al
    Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3).
    Neuro Oncol. 2022 Oct 10. pii: 6755369. doi: 10.1093.
    PubMed     Abstract available


  38. GONZALEZ CASTRO LN, Liu I, Filbin M
    Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
    Neuro Oncol. 2022 Oct 5. pii: 6748723. doi: 10.1093.
    PubMed     Abstract available


  39. OSTROM QT, Price M, Neff C, Cioffi G, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  40. KUMTHEKAR P, Nagpal S
    Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease.
    Neuro Oncol. 2022;24:1687-1688.
    PubMed    


  41. LUKAS RV
    Leptomeningeal metastases-What outcomes should we measure and how?
    Neuro Oncol. 2022;24:1736-1737.
    PubMed    


  42. BOCKMAYR M, Harnisch K, Pohl LC, Schweizer L, et al
    Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.
    Neuro Oncol. 2022;24:1689-1699.
    PubMed     Abstract available


  43. LAW V, Chen Z, Vena F, Smalley I, et al
    A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
    Neuro Oncol. 2022;24:1673-1686.
    PubMed     Abstract available


  44. LE RHUN E, Devos P, Winklhofer S, Lmalem H, et al
    Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
    Neuro Oncol. 2022;24:1726-1735.
    PubMed     Abstract available


    September 2022
  45. LIN B, Ziebro J, Smithberger E, Skinner KR, et al
    EGFR, the Lazarus target for precision oncology in glioblastoma.
    Neuro Oncol. 2022 Sep 19. pii: 6705404. doi: 10.1093.
    PubMed     Abstract available


  46. HOFFMAN LM, Jaimes C, Mankad K, Mirsky DM, et al
    Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
    Neuro Oncol. 2022 Sep 17. pii: 6702540. doi: 10.1093.
    PubMed     Abstract available


  47. KASHANI E, Schnidrig D, Hashemi Gheinani A, Ninck MS, et al
    Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
    Neuro Oncol. 2022 Sep 17. pii: 6702539. doi: 10.1093.
    PubMed     Abstract available


  48. OSTROM QT, Price M, Ryan K, Edelson J, et al
    CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  49. STEJEREAN-TODORAN I, Gimotty PA, Watters A, Brafford P, et al
    A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
    Neuro Oncol. 2022 Sep 2. pii: 6687782. doi: 10.1093.
    PubMed     Abstract available


  50. INDELICATO DJ
    No question: Proton therapy is safe.
    Neuro Oncol. 2022;24:1582-1583.
    PubMed    


    August 2022
  51. YU K, Kong K, Lozzi B, Luna-Figueroa E, et al
    In Vivo Functional Characterization of EGFR Variants Identifies Novel Drivers of Glioblastoma.
    Neuro Oncol. 2022 Aug 31. pii: 6679484. doi: 10.1093.
    PubMed     Abstract available


  52. BEDDOK A, Scher N, Alapetite C, Baussart B, et al
    Protontherapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients.
    Neuro Oncol. 2022 Aug 25. pii: 6674791. doi: 10.1093.
    PubMed     Abstract available


  53. OSTROM QT, Shoaf ML, Cioffi G, Waite K, et al
    National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Neuro Oncol. 2022 Aug 22. pii: 6673397. doi: 10.1093.
    PubMed     Abstract available


  54. YOUNGBLOOD MW, Tran AN, Wang W, An S, et al
    Docetaxel Targets Aggressive Methylation Profiles and Serves as a Radiosensitizer in High-Risk Meningiomas.
    Neuro Oncol. 2022 Aug 17. pii: 6670614. doi: 10.1093.
    PubMed     Abstract available


  55. SHI DD, Youssef GC, Nassar AH, Lim-Fat MJ, et al
    Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Aug 16. pii: 6668736. doi: 10.1093.
    PubMed    


  56. VAN OPIJNEN MP, Tesileanu CMS, Dirven L, van der Meer PB, et al
    IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
    Neuro Oncol. 2022 Aug 16. pii: 6668487. doi: 10.1093.
    PubMed     Abstract available


  57. KARSCHNIA P, Young JS, Dono A, Hani L, et al
    Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group.
    Neuro Oncol. 2022 Aug 12. pii: 6664041. doi: 10.1093.
    PubMed     Abstract available


  58. SEYVE A, Dehais C, Chinot O, Djelad A, et al
    Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study.
    Neuro Oncol. 2022 Aug 12. pii: 6661438. doi: 10.1093.
    PubMed     Abstract available


  59. LUO X, Yang Y, Yin S, Li H, et al
    False-negative and false-positive outcomes of computer aided detection on brain metastasis: secondary analysis of a multicenter, multireader study.
    Neuro Oncol. 2022 Aug 9. pii: 6658946. doi: 10.1093.
    PubMed     Abstract available


  60. RUDA R, Capper D, Waldman AD, Pallud J, et al
    Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors.
    Neuro Oncol. 2022 Aug 1. pii: 6652587. doi: 10.1093.
    PubMed     Abstract available


  61. BOELE FW, den Otter PWM, Reijneveld JC, de Witt Hamer PC, et al
    Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades.
    Neuro Oncol. 2022 Aug 1. pii: 6652588. doi: 10.1093.
    PubMed     Abstract available


  62. VARADHARAJAN S, Mack SC
    Leveraging epigenomic patterns to resolve the heterogeneity and origins of CNS germ cell tumors.
    Neuro Oncol. 2022;24:1259-1260.
    PubMed    


  63. DESJARDINS A
    Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.
    Neuro Oncol. 2022;24:1350-1351.
    PubMed    


  64. YAO H, Xie W, Dai Y, Liu Y, et al
    TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
    Neuro Oncol. 2022;24:1286-1297.
    PubMed     Abstract available


  65. TAKAMI H, Elzawahry A, Mamatjan Y, Fukushima S, et al
    Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.
    Neuro Oncol. 2022;24:1246-1258.
    PubMed     Abstract available


  66. KOH KN, Wong RX, Lee DE, Han JW, et al
    Outcomes of intracranial germinoma-A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies.
    Neuro Oncol. 2022;24:1389-1399.
    PubMed     Abstract available


    July 2022
  67. HERTLER C, Seystahl K, Le Rhun E, Wirsching HG, et al
    Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
    Neuro Oncol. 2022 Jul 30. pii: 6652283. doi: 10.1093.
    PubMed    



  68. Erratum to: Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2022 Jul 29. pii: 6651886. doi: 10.1093.
    PubMed    


  69. CHEN AT, Xiao Y, Tang X, Baqri M, et al
    Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.
    Neuro Oncol. 2022 Jul 28. pii: 6651351. doi: 10.1093.
    PubMed     Abstract available


  70. SIGAUD R, Rosch L, Gatzweiler C, Benzel J, et al
    The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.
    Neuro Oncol. 2022 Jul 27. pii: 6650335. doi: 10.1093.
    PubMed     Abstract available


  71. DREXLER R, Schuller U, Eckhardt A, Filipski K, et al
    DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Neuro Oncol. 2022 Jul 22. pii: 6648783. doi: 10.1093.
    PubMed     Abstract available


  72. WALSH KM, Neff C, Bondy ML, Kruchko C, et al
    Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Jul 22. pii: 6648782. doi: 10.1093.
    PubMed     Abstract available


  73. KOSTI A, Chiou J, Guardia GDA, Lei X, et al
    ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics.
    Neuro Oncol. 2022 Jul 21. pii: 6648020. doi: 10.1093.
    PubMed     Abstract available


  74. LASSMAN AB, Pugh SL, Wang TJC, Aldape K, et al
    Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.
    Neuro Oncol. 2022 Jul 15. pii: 6645128. doi: 10.1093.
    PubMed     Abstract available


  75. BUEHLER M, Yi X, Ge W, Blattmann P, et al
    Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions.
    Neuro Oncol. 2022 Jul 8. pii: 6634186. doi: 10.1093.
    PubMed     Abstract available


  76. REYES-GONZALEZ J, Barajas-Olmos F, Garcia-Ortiz H, Magraner-Pardo L, et al
    Brain Radiotoxicity-Related 15CAcBRT Gene Expression Signature Predicts Survival Prognosis of Glioblastoma Patients.
    Neuro Oncol. 2022 Jul 8. pii: 6634161. doi: 10.1093.
    PubMed     Abstract available


  77. VAN DER VOORT SR, Incekara F, Wijnenga MMJ, Kapsas G, et al
    Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning.
    Neuro Oncol. 2022 Jul 5. pii: 6631283. doi: 10.1093.
    PubMed     Abstract available


  78. HUSE JT
    A Promising Preclinical Model For Tert Promoter Mutation In Glioblastoma.
    Neuro Oncol. 2022 Jul 3. pii: 6628220. doi: 10.1093.
    PubMed    


  79. DONAHUE BR, MacDonald S
    Protons for pediatric ependymoma: Where are we now?
    Neuro Oncol. 2022;24:1203-1204.
    PubMed    


  80. MILLWARD CP, Armstrong TS, Barrington H, Brodbelt AR, et al
    Opportunities and challenges for the development of "core outcome sets" in neuro-oncology.
    Neuro Oncol. 2022;24:1048-1055.
    PubMed     Abstract available


  81. HERRGOTT GA, Asmaro KP, Wells M, Sabedot TS, et al
    Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Neuro Oncol. 2022;24:1126-1139.
    PubMed     Abstract available


  82. PETERS S, Merta J, Schmidt L, Jazmati D, et al
    Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.
    Neuro Oncol. 2022;24:1193-1202.
    PubMed     Abstract available


    June 2022
  83. PALMER JD, Prasad RN, Cioffi G, Kruchtko C, et al
    Exposure to Radon and Heavy Particulate Pollution and Incidence of Brain Tumors.
    Neuro Oncol. 2022 Jun 28. pii: 6618967. doi: 10.1093.
    PubMed     Abstract available


  84. AIZER AA, Lamba N, Ahluwalia MS, Aldape K, et al
    Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
    Neuro Oncol. 2022 Jun 28. pii: 6618874. doi: 10.1093.
    PubMed     Abstract available


  85. NOBRE L, Bouffet E
    BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence?
    Neuro Oncol. 2022 Jun 24. pii: 6617660. doi: 10.1093.
    PubMed    


  86. WEISHAUPT H, Cancer M, Rosen G, Holmberg KO, et al
    Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
    Neuro Oncol. 2022 Jun 23. pii: 6615415. doi: 10.1093.
    PubMed     Abstract available


  87. CHEN X, Niu W, Fan X, Yang H, et al
    Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
    Neuro Oncol. 2022 Jun 21. pii: 6612239. doi: 10.1093.
    PubMed     Abstract available


  88. WANG Y, Wang K, Fu J, Zhang Y, et al
    FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1.
    Neuro Oncol. 2022 Jun 20. pii: 6611687. doi: 10.1093.
    PubMed     Abstract available


  89. NATSUME A, Arakawa Y, Narita Y, Sugiyama K, et al
    The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
    Neuro Oncol. 2022 Jun 20. pii: 6611503. doi: 10.1093.
    PubMed     Abstract available


  90. LIU XP, Jin X, Ahmadian SS, Yang X, et al
    Clinical Significance and Molecular Annotation of Cellular Morphometric Subtypes in Lower Grade Gliomas discovered by Machine Learning.
    Neuro Oncol. 2022 Jun 18. pii: 6611075. doi: 10.1093.
    PubMed     Abstract available


  91. OSTROM QT, Lu D, Lu R, Baker MC, et al
    Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.
    Neuro Oncol. 2022 Jun 17. pii: 6609733. doi: 10.1093.
    PubMed    


  92. SARAF A, Yock TI, Niemierko A, Oh KS, et al
    Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience.
    Neuro Oncol. 2022 Jun 7. pii: 6603917. doi: 10.1093.
    PubMed     Abstract available


  93. LEE-CHANG C
    Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy.
    Neuro Oncol. 2022 Jun 6. pii: 6602133. doi: 10.1093.
    PubMed    


  94. ROGERS CL, Pugh SL, Vogelbaum MA, Perry A, et al
    Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539.
    Neuro Oncol. 2022 Jun 3. pii: 6601387. doi: 10.1093.
    PubMed     Abstract available


  95. TAYLOR JW, Weyer-Jamora C, Hervey-Jumper S
    Molecularly determining cognition in glioma: New insights as the plot thickens.
    Neuro Oncol. 2022 Jun 3. pii: 6601533. doi: 10.1093.
    PubMed    


  96. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Standardizing reporting of brain and central nervous system tumors in the United Kingdom.
    Neuro Oncol. 2022;24:1032-1033.
    PubMed    


  97. MANGUM R, Parsons DW
    TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.
    Neuro Oncol. 2022;24:1008-1009.
    PubMed    


  98. FAROUK SAIT S, Karajannis MA
    Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
    Neuro Oncol. 2022;24:984-985.
    PubMed    


  99. CAI F, Chen S, Yu X, Zhang J, et al
    Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.
    Neuro Oncol. 2022;24:925-935.
    PubMed     Abstract available


  100. BARTELS U, Onar-Thomas A, Patel SK, Shaw D, et al
    Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
    Neuro Oncol. 2022;24:974-983.
    PubMed     Abstract available


  101. PARK AK, Waheed A, Forst DA, Al-Samkari H, et al
    Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
    Neuro Oncol. 2022;24:964-973.
    PubMed     Abstract available


    May 2022

  102. Erratum to: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2022 May 27. pii: 6594729. doi: 10.1093.
    PubMed    


  103. NOBRE L, Hawkins C
    Liquid biopsy for pediatric brain tumor patients: is it prime time yet?
    Neuro Oncol. 2022 May 27. pii: 6593987. doi: 10.1093.
    PubMed    


  104. VERPLOEGH ISC, Conidi A, Brouwer RWW, Balcioglu HE, et al
    Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.
    Neuro Oncol. 2022 May 26. pii: 6593858. doi: 10.1093.
    PubMed     Abstract available


  105. DE LA FUENTE MI, Colman H, Rosenthal M, Van Tine BA, et al
    Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
    Neuro Oncol. 2022 May 25. pii: 6593129. doi: 10.1093.
    PubMed     Abstract available


  106. FRIEDRICH M, Hahn M, Michel J, Sankowski R, et al
    Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Neuro Oncol. 2022 May 24. pii: 6591514. doi: 10.1093.
    PubMed     Abstract available


  107. GRIGUOLO G, Tosi A, Dieci MV, Fineberg S, et al
    A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.
    Neuro Oncol. 2022 May 24. pii: 6591493. doi: 10.1093.
    PubMed     Abstract available


  108. MESSINGER D, Harris MK, Cummings JR, Thomas C, et al
    Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
    Neuro Oncol. 2022 May 23. pii: 6590903. doi: 10.1093.
    PubMed     Abstract available


  109. YEO KK, Alexandrescu S, Cotter JA, Vogelzang J, et al
    Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
    Neuro Oncol. 2022 May 23. pii: 6590765. doi: 10.1093.
    PubMed     Abstract available


  110. GIRARDI F, Coleman MP, Allemani C
    Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al".
    Neuro Oncol. 2022 May 21. pii: 6590321. doi: 10.1093.
    PubMed    


  111. HOOGENDIJK R, van der Lugt J, van Vuurden DG, Visser O, et al
    Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al.
    Neuro Oncol. 2022 May 21. pii: 6590318. doi: 10.1093.
    PubMed    


  112. EDMONSTON DY, Wu S, Li Y, Khan RB, et al
    Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 May 12. pii: 6585053. doi: 10.1093.
    PubMed     Abstract available


  113. SAMPETREAN O, Saya H
    What can metabolites tell us about gliomas?
    Neuro Oncol. 2022 May 12. pii: 6584800. doi: 10.1093.
    PubMed    


  114. BARTLETT A, Lane A, Chaney B, Escorza NY, et al
    Characteristics of Children
    Neuro Oncol. 2022 May 12. pii: 6585024. doi: 10.1093.
    PubMed     Abstract available


  115. RICKLEFS FL, Maire CL, Wollmann K, Duhrsen L, et al
    Diagnostic potential of extracellular vesicles in meningioma patients.
    Neuro Oncol. 2022 May 12. pii: 6585054. doi: 10.1093.
    PubMed     Abstract available


  116. REED-GUY L, Desai AS, Phillips RE, Croteau D, et al
    Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Neuro Oncol. 2022 May 12. pii: 6585055. doi: 10.1093.
    PubMed     Abstract available


  117. ROESLER R, de Farias CB, Brunetto AT, Gregianin L, et al
    Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Neuro Oncol. 2022 May 11. pii: 6584501. doi: 10.1093.
    PubMed    



  118. Erratum to: path-03. Ferroptosis-related long non-coding rna signatures predict prognosis in patients with glioma.
    Neuro Oncol. 2022 May 9. pii: 6583332. doi: 10.1093.
    PubMed    


  119. WINKLER F
    Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.
    Neuro Oncol. 2022 May 9. pii: 6582767. doi: 10.1093.
    PubMed    


  120. GALLDIKS N, Lohmann P, Langen KJ
    The role of 11C-methionine PET in patients with newly diagnosed WHO grade 2 or 3 gliomas.
    Neuro Oncol. 2022 May 5. pii: 6581471. doi: 10.1093.
    PubMed    


  121. CASES-CUNILLERA S, van Loo KMJ, Pitsch J, Quatraccioni A, et al
    Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
    Neuro Oncol. 2022;24:741-754.
    PubMed     Abstract available


  122. SATOMI K, Takami H, Fukushima S, Yamashita S, et al
    12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:834-846.
    PubMed     Abstract available


  123. LAZOW MA, Fuller C, DeWire M, Lane A, et al
    Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
    Neuro Oncol. 2022;24:821-833.
    PubMed     Abstract available


  124. RUDA R, Bruno F, Ius T, Silvani A, et al
    IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
    Neuro Oncol. 2022;24:809-820.
    PubMed     Abstract available


  125. FELIX M, Friedel D, Jayavelu AK, Filipski K, et al
    HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Neuro Oncol. 2022 May 3. pii: 6578556. doi: 10.1093.
    PubMed     Abstract available


  126. RICKLEFS FL, Drexler R, Wollmann K, Eckhardt A, et al
    DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
    Neuro Oncol. 2022 May 2. pii: 6577052. doi: 10.1093.
    PubMed     Abstract available


  127. LIM M, Weller M, Idbaih A, Steinbach J, et al
    Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.
    Neuro Oncol. 2022 May 2. pii: 6577049. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  128. PERSSON ML, Douglas AM, Alvaro F, Faridi P, et al
    The intrinsic and microenvironmental features of diffuse midline glioma; implications for the development of effective immunotherapeutic treatment strategies.
    Neuro Oncol. 2022 Apr 27. pii: 6575144. doi: 10.1093.
    PubMed     Abstract available


  129. MERCHANT TE, Edmonston DY, Wu S, Li Y, et al
    Endocrine Outcomes after Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 Apr 27. pii: 6575137. doi: 10.1093.
    PubMed     Abstract available


  130. DING J, Li X, Khan S, Zhang C, et al
    EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
    Neuro Oncol. 2022 Apr 26. pii: 6574563. doi: 10.1093.
    PubMed     Abstract available


  131. GUTIERREZ-VALENCIA E, Kalyvas A, Villafuerte CJ, Millar BA, et al
    Factors Correlating with Survival Following Adjuvant or Definitive Radiosurgery for Large Brain Metastases.
    Neuro Oncol. 2022 Apr 26. pii: 6574580. doi: 10.1093.
    PubMed     Abstract available


  132. JAIN B, Dee EC, Jain U, Aizer AA, et al
    Trends in location of death for individuals with primary brain tumors in the United States.
    Neuro Oncol. 2022 Apr 26. pii: 6574444. doi: 10.1093.
    PubMed    


  133. SCHONROCK A, Heinzelmann E, Steffl B, Demirdizen E, et al
    MEOX2 homeobox gene promotes growth of malignant gliomas.
    Neuro Oncol. 2022 Apr 25. pii: 6573906. doi: 10.1093.
    PubMed     Abstract available


  134. MA R, Rei M, Woodhouse I, Ferris K, et al
    Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.
    Neuro Oncol. 2022 Apr 25. pii: 6573935. doi: 10.1093.
    PubMed     Abstract available


  135. MINAMI N, Hong D, Stevers N, Barger CJ, et al
    Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
    Neuro Oncol. 2022 Apr 23. pii: 6573305. doi: 10.1093.
    PubMed     Abstract available


  136. IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
    Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
    Neuro Oncol. 2022 Apr 23. pii: 6573306. doi: 10.1093.
    PubMed     Abstract available


  137. CHUNG C, Brown PD, Wefel JS
    Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial.
    Neuro Oncol. 2022 Apr 23. pii: 6573235. doi: 10.1093.
    PubMed    


  138. PUROW B
    ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma.
    Neuro Oncol. 2022 Apr 23. pii: 6573255. doi: 10.1093.
    PubMed    


  139. OMURO A, Brandes AA, Carpentier AF, Idbaih A, et al
    Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
    Neuro Oncol. 2022 Apr 14. pii: 6568419. doi: 10.1093.
    PubMed     Abstract available


  140. COUTURIER CP, Nadaf J, Li Z, Baig S, et al
    Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells.
    Neuro Oncol. 2022 Apr 13. pii: 6567757. doi: 10.1093.
    PubMed     Abstract available


  141. COOMANS M, Dirven L, Aaronson N, Baumert BG, et al
    Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
    Neuro Oncol. 2022 Apr 11. pii: 6566436. doi: 10.1093.
    PubMed     Abstract available


  142. GHOSH S
    Breaking the DLG shackles in glioblastoma.
    Neuro Oncol. 2022 Apr 11. pii: 6566243. doi: 10.1093.
    PubMed    


  143. ROSENBERG T, Yeo KK, Mauguen A, Alexandrescu S, et al
    Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566011. doi: 10.1093.
    PubMed     Abstract available


  144. ZHANG L, Nesvick CL, Day CA, Choi J, et al
    STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566009. doi: 10.1093.
    PubMed     Abstract available


  145. KANMOUNYE US, Karekezi C, Nyalundja AD, Awad AK, et al
    Adult brain tumors in Sub-Saharan Africa: A scoping review.
    Neuro Oncol. 2022 Apr 9. pii: 6566010. doi: 10.1093.
    PubMed     Abstract available


  146. ZHANG Y, Lucas CG, Young JS, Morshed RA, et al
    Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Neuro Oncol. 2022 Apr 8. pii: 6565639. doi: 10.1093.
    PubMed     Abstract available


  147. BIEGEL JA
    Meeting the high expectations for liquid biopsy assays for pediatric brain tumors: progress and challenges.
    Neuro Oncol. 2022 Apr 5. pii: 6563880. doi: 10.1093.
    PubMed    


  148. ELLINGSON BM, Gerstner ER, Lassman AB, Chung C, et al
    Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.
    Neuro Oncol. 2022 Apr 5. pii: 6563738. doi: 10.1093.
    PubMed     Abstract available


  149. TESILEANU CMS, Gorlia T, Golfinopoulos V, French PJ, et al
    MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
    Neuro Oncol. 2022;24:665-667.
    PubMed    


  150. FRAPPAZ D, Dhall G, Murray MJ, Goldman S, et al
    EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults.
    Neuro Oncol. 2022;24:516-527.
    PubMed     Abstract available


  151. NAKAMURA H, Takami H, Yanagisawa T, Kumabe T, et al
    The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:503-515.
    PubMed     Abstract available


  152. WU Z, Abdullaev Z, Pratt D, Chung HJ, et al
    Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.
    Neuro Oncol. 2022;24:571-581.
    PubMed     Abstract available


    March 2022
  153. SARAN F, Eisenstat DD
    The relapse doesn't fall far from the radiotherapy field: Lessons to be learned for the future of radiotherapy in medulloblastoma from the relapse patterns of SJMB03.
    Neuro Oncol. 2022 Mar 24. pii: 6553345. doi: 10.1093.
    PubMed    


  154. PIOTROWSKI AF, Jackson S
    Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol. 2022 Mar 23. pii: 6553267. doi: 10.1093.
    PubMed    


  155. CORDELL EC, Alghamri MS, Castro MG, Gutmann DH, et al
    T lymphocytes as dynamic regulators of glioma pathobiology.
    Neuro Oncol. 2022 Mar 23. pii: 6553145. doi: 10.1093.
    PubMed     Abstract available


  156. OSUKA S
    Targeting adaptive radioresistance in Glioblastoma.
    Neuro Oncol. 2022 Mar 22. pii: 6552309. doi: 10.1093.
    PubMed    


  157. BLOBNER J, Tonn JC
    Resection of glioma - Feeding the beast?
    Neuro Oncol. 2022 Mar 22. pii: 6552311. doi: 10.1093.
    PubMed    


  158. AZAD TD, Bettegowda C
    Longitudinal monitoring of diffuse midline glioma using liquid biopsy.
    Neuro Oncol. 2022 Mar 22. pii: 6552310. doi: 10.1093.
    PubMed    


  159. LE RHUN E, Oppong FB, Vanlancker M, Stupp R, et al
    Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Mar 21. pii: 6551573. doi: 10.1093.
    PubMed     Abstract available


  160. ZHAN Q, Yi K, Cui X, Li X, et al
    Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy.
    Neuro Oncol. 2022 Mar 21. pii: 6551550. doi: 10.1093.
    PubMed     Abstract available


  161. QIN N, Paisana E, Langini M, Picard D, et al
    Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
    Neuro Oncol. 2022 Mar 21. pii: 6551011. doi: 10.1093.
    PubMed     Abstract available


  162. FANGUSARO JR, Onar-Thomas A, Poussaint TY, Wu S, et al
    Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
    Neuro Oncol. 2022 Mar 21. pii: 6551018. doi: 10.1093.
    PubMed    


  163. FERDOSI SR, Taylor B, Lee M, Tang N, et al
    PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
    Neuro Oncol. 2022 Mar 19. pii: 6550856. doi: 10.1093.
    PubMed     Abstract available


  164. BOUFFET E, Lafay-Cousin L
    Infant brain tumor trials: Beyond feasibility.
    Neuro Oncol. 2022 Mar 14. pii: 6548388. doi: 10.1093.
    PubMed    


  165. ZHOU Y, Meng X, He W, Li XY, et al
    USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.
    Neuro Oncol. 2022 Mar 14. pii: 6548387. doi: 10.1093.
    PubMed     Abstract available


  166. MOHAMED E, Kumar A, Zhang Y, Wang AS, et al
    PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Neuro Oncol. 2022 Mar 14. pii: 6548389. doi: 10.1093.
    PubMed     Abstract available


  167. FOREMAN NK
    Outcomes after first relapse of children with intracranial ependymoma treated on the second l'Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) protocol.
    Neuro Oncol. 2022;24:480-481.
    PubMed    


  168. MILLER JJ, Wang N
    Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation.
    Neuro Oncol. 2022;24:492-493.
    PubMed    


  169. MASSIMINO M, Barretta F, Modena P, Johann P, et al
    Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.
    Neuro Oncol. 2022;24:467-479.
    PubMed     Abstract available


  170. BURGENSKE DM, Talele S, Pokorny JL, Mladek AC, et al
    Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
    Neuro Oncol. 2022;24:384-395.
    PubMed     Abstract available


  171. MILLER JJ, Cahill DP, Arrillaga-Romany I
    Enhancing demethylation-induced differentiation in IDH-mutant glioma.
    Neuro Oncol. 2022 Mar 3. pii: 6542042. doi: 10.1093.
    PubMed    


  172. MLADEK AC, Yan H, Tian S, Decker PA, et al
    RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.
    Neuro Oncol. 2022 Mar 1. pii: 6540482. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  173. BADODI S, Pomella N, Lim YM, Brandner S, et al
    Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
    Neuro Oncol. 2022 Feb 25. pii: 6537125. doi: 10.1093.
    PubMed     Abstract available


  174. PAPUSHA L, Zaytseva M, Panferova A, Druy A, et al
    Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
    Neuro Oncol. 2022 Feb 23. pii: 6535118. doi: 10.1093.
    PubMed    


  175. FERRARESE R, Carro MS
    Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.
    Neuro Oncol. 2022 Feb 19. pii: 6532496. doi: 10.1093.
    PubMed    


  176. NINATTI G, Sollini M, Bono B, Gozzi N, et al
    Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
    Neuro Oncol. 2022 Feb 16. pii: 6529477. doi: 10.1093.
    PubMed     Abstract available


  177. UPADHYAY R, Liao K, Grosshans DR, McGovern SL, et al
    Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors.
    Neuro Oncol. 2022 Feb 14. pii: 6528473. doi: 10.1093.
    PubMed     Abstract available


  178. PRZYSTAL JM, Cosentino CC, Yadavilli S, Zhang J, et al
    Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Neuro Oncol. 2022 Feb 14. pii: 6528446. doi: 10.1093.
    PubMed     Abstract available


  179. BJORKBLOM B, Wibom C, Eriksson M, Bergenheim AT, et al
    Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
    Neuro Oncol. 2022 Feb 14. pii: 6528465. doi: 10.1093.
    PubMed     Abstract available


  180. LIU T, Zhu C, Chen X, Guan G, et al
    Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
    Neuro Oncol. 2022 Feb 11. pii: 6527229. doi: 10.1093.
    PubMed     Abstract available


  181. MILLER AM, Szalontay L, Bouvier N, Hill K, et al
    Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients.
    Neuro Oncol. 2022 Feb 11. pii: 6527231. doi: 10.1093.
    PubMed     Abstract available


  182. VAN KESSEL E, Berendsen S, Baumfalk AE, Venugopal H, et al
    Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.
    Neuro Oncol. 2022 Feb 11. pii: 6527233. doi: 10.1093.
    PubMed     Abstract available


  183. LAZOW MA, Nievelstein MT, Lane A, Bandopadhayhay P, et al
    Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
    Neuro Oncol. 2022 Feb 11. pii: 6527234. doi: 10.1093.
    PubMed     Abstract available


  184. REBCHUK AD, Chaharyn BM, Alam A, Hounjet CD, et al
    The Impact of Brain Invasion Criteria on the Incidence and Distribution of WHO Grade 1, 2 and 3 Meningiomas.
    Neuro Oncol. 2022 Feb 9. pii: 6525422. doi: 10.1093.
    PubMed     Abstract available


  185. JO J, van den Bent MJ, Nabors B, Wen PY, et al
    Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
    Neuro Oncol. 2022 Feb 8. pii: 6524653. doi: 10.1093.
    PubMed     Abstract available


  186. CANTOR E, Wierzbicki K, Tarapore RS, Ravi K, et al
    Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Neuro Oncol. 2022 Feb 6. pii: 6523277. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  187. YIN S, Luo X, Yang Y, Shao Y, et al
    Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study.
    Neuro Oncol. 2022 Jan 31. pii: 6518101. doi: 10.1093.
    PubMed     Abstract available


  188. ALVAREZ-BRECKENRIDGE CA, Cahill DP, Brastianos PK
    Trabectedin for recurrent WHO grade 2 or 3 meningiomas-paving the road for new opportunities.
    Neuro Oncol. 2022 Jan 31. pii: 6518099. doi: 10.1093.
    PubMed    


  189. READ RD
    Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518098. doi: 10.1093.
    PubMed    


  190. BROWN CE, Rodriguez A, Palmer J, Ostberg JR, et al
    Off-the-shelf, Steroid Resistant, IL13Ralpha2-Specific CAR T Cells for Treatment of Glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518100. doi: 10.1093.
    PubMed     Abstract available


  191. LOWE SR, Wang CP, Brisco A, Whiting J, et al
    Surgical and Anatomic Factors Predict Development of Leptomeningeal Disease in Patients with Melanoma Brain Metastases.
    Neuro Oncol. 2022 Jan 29. pii: 6517353. doi: 10.1093.
    PubMed     Abstract available


  192. TAGLANG C, Batsios G, Mukherjee J, Tran M, et al
    Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
    Neuro Oncol. 2022 Jan 29. pii: 6517050. doi: 10.1093.
    PubMed     Abstract available


  193. GERSTNER ER
    Volumetric Measurements in Low Grade Glioma: Are we there yet?
    Neuro Oncol. 2022 Jan 28. pii: 6516793. doi: 10.1093.
    PubMed    


  194. KOEKKOEK JAF, van der Meer PB, Taphoorn MJB, Dirven L, et al
    Letter regarding "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors".
    Neuro Oncol. 2022 Jan 25. pii: 6515357. doi: 10.1093.
    PubMed    


  195. PICCA A, Desjardins C, Bihan K, Weiss N, et al
    Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
    Neuro Oncol. 2022 Jan 17. pii: 6509380. doi: 10.1093.
    PubMed    


  196. RAHMAN R, Huang RY
    Deep learning approaches to non-invasively assess molecular features of gliomas.
    Neuro Oncol. 2022 Jan 13. pii: 6507359. doi: 10.1093.
    PubMed    


  197. VOGELIUS IR, Bentzen SM
    Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.
    Neuro Oncol. 2022 Jan 13. pii: 6506534. doi: 10.1093.
    PubMed    


  198. BECKER KN, Eisenmann KM
    New Targets in the Glioblastoma Tumor Microtube Multiverse: Emerging Roles for the TGF-beta/TSP1 Signaling Axis.
    Neuro Oncol. 2022 Jan 10. pii: 6502470. doi: 10.1093.
    PubMed    


  199. TRAN AN
    Targeting glutamine addiction in meningioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502476. doi: 10.1093.
    PubMed    


  200. ESPINOZA FI, Walker PR
    Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition.
    Neuro Oncol. 2022 Jan 10. pii: 6502489. doi: 10.1093.
    PubMed    


  201. VOGELBAUM MA
    Balancing Maximal Resection and Functional Preservation in Surgery for Low Grade Glioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502479. doi: 10.1093.
    PubMed    


  202. KOTCH C, Avery R, Getz KD, Bouffet E, et al
    Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
    Neuro Oncol. 2022 Jan 9. pii: 6501465. doi: 10.1093.
    PubMed     Abstract available


  203. MAEGAWA S, Gopalakrishnan V
    PLK inhibitors come of age in pediatric brain tumors.
    Neuro Oncol. 2022 Jan 7. pii: 6499977. doi: 10.1093.
    PubMed    


  204. SOFFIETTI R, Bettegowda C, Mellinghoff IK, Warren KE, et al
    Liquid biopsy in gliomas: a RANO review and proposals for clinical applications.
    Neuro Oncol. 2022 Jan 6. pii: 6499389. doi: 10.1093.
    PubMed     Abstract available


  205. MORTAZAVI A, Fayed I, Bachani M, Dowdy T, et al
    IDH Mutated Gliomas Promote Epileptogenesis through D-2-Hydroxyglutarate Dependent mTOR Hyperactivation.
    Neuro Oncol. 2022 Jan 5. pii: 6498134. doi: 10.1093.
    PubMed     Abstract available


  206. FURLAN JC, Wilson JR, Massicotte EM, Sahgal A, et al
    Recent advances and new discoveries in the pipeline of the treatment of primary spinal tumors and spinal metastases: a scoping review of registered clinical studies from 2000 to 2020.
    Neuro Oncol. 2022;24:1-13.
    PubMed     Abstract available


  207. JUHNKE BO, Gessi M, Gerber NU, Friedrich C, et al
    Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial.
    Neuro Oncol. 2022;24:127-137.
    PubMed     Abstract available


  208. LAMBA N, Catalano PJ, Bi WL, Wen PY, et al
    Predictors of long-term survival among patients with brain metastases.
    Neuro Oncol. 2022 Jan 4. pii: 6497420. doi: 10.1093.
    PubMed    


  209. KUNDU S, Nandhu MS, Longo SL, Longo JA, et al
    The scaffolding protein DLG5 promotes glioblastoma growth by controlling Sonic Hedgehog signaling in tumor stem cells.
    Neuro Oncol. 2022 Jan 4. pii: 6497518. doi: 10.1093.
    PubMed     Abstract available


  210. PAGES M, Rotem D, Gydush G, Reed S, et al
    Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Neuro Oncol. 2022 Jan 4. pii: 6497435. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  211. DE BILLY E, Pellegrino M, Orlando D, Pericoli G, et al
    Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    Neuro Oncol. 2021 Dec 29. pii: 6489024. doi: 10.1093.
    PubMed     Abstract available


  212. KNUDSEN AM, Halle B, Cedile O, Burton M, et al
    Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
    Neuro Oncol. 2021 Dec 29. pii: 6489042. doi: 10.1093.
    PubMed     Abstract available


  213. HU C, Wang K, Damon C, Fu Y, et al
    ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
    Neuro Oncol. 2021 Dec 24. pii: 6482823. doi: 10.1093.
    PubMed     Abstract available


  214. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
    Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
    Neuro Oncol. 2021 Dec 22. pii: 6478897. doi: 10.1093.
    PubMed     Abstract available


  215. LEARY SES, Lindsay K, Geyer JR, Mehmet K, et al
    Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
    Neuro Oncol. 2021 Dec 22. pii: 6478443. doi: 10.1093.
    PubMed     Abstract available


  216. DESHPANDE K, Martirosian V, Nakamura BN, Iyer M, et al
    Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
    Neuro Oncol. 2021 Dec 21. pii: 6473228. doi: 10.1093.
    PubMed     Abstract available


  217. YABO YA, Niclou SP, Golebiewska A
    Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2021 Dec 21. pii: 6472977. doi: 10.1093.
    PubMed     Abstract available


  218. GU J, Mu N, Jia B, Guo Q, et al
    Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.
    Neuro Oncol. 2021 Dec 14. pii: 6461092. doi: 10.1093.
    PubMed     Abstract available


  219. LUCAS JT, Tinkle CL, Huang J, Onar-Thomas A, et al
    Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
    Neuro Oncol. 2021 Dec 11. pii: 6459719. doi: 10.1093.
    PubMed     Abstract available


  220. LIM-FAT MJ, Youssef GC, Touat M, Iorgulescu JB, et al
    Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
    Neuro Oncol. 2021 Dec 8. pii: 6456497. doi: 10.1093.
    PubMed     Abstract available


  221. GARZIA L
    Faraway, so close: intratumoral heterogeneity of medulloblastoma subgroups.
    Neuro Oncol. 2021 Dec 4. pii: 6449209. doi: 10.1093.
    PubMed    


  222. HAGIWARA A, Oughourlian TC, Cho NS, Schlossman J, et al
    Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2021 Dec 2. pii: 6448328. doi: 10.1093.
    PubMed     Abstract available


  223. GUPTA T, Manjali JJ, Purandare N, Bagal B, et al
    Bone marrow biopsy in PCNSL: Relevant or redundant?
    Neuro Oncol. 2021;23:2117-2118.
    PubMed    


  224. MARGOLD M, Schlegel U
    Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?
    Neuro Oncol. 2021;23:2119.
    PubMed    


  225. MOUDGIL-JOSHI J, Kaliaperumal C
    Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.
    Neuro Oncol. 2021;23:2120-2121.
    PubMed    


  226. ECKEL-PASSOW JE, Kitange GJ, Decker PA, Kosel ML, et al
    Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
    Neuro Oncol. 2021;23:2066-2075.
    PubMed     Abstract available


  227. MARNER L, Lundemann M, Sehested A, Nysom K, et al
    Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.
    Neuro Oncol. 2021;23:2107-2116.
    PubMed     Abstract available


    November 2021
  228. CHAREST A
    Optimizing an effective combination of the new microtubule targeting agent Lisavanbulin with standard of care therapy for glioblastoma in patient-derived xenograft pre-clinical models.
    Neuro Oncol. 2021 Nov 27. pii: 6444804. doi: 10.1093.
    PubMed    


  229. TAYLOR JW
    Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high grade glioma?
    Neuro Oncol. 2021 Nov 27. pii: 6444703. doi: 10.1093.
    PubMed    


  230. LEMAITRE AL, Herbet G, Ng S, Moritz-Gasser S, et al
    Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study.
    Neuro Oncol. 2021 Nov 26. pii: 6444171. doi: 10.1093.
    PubMed     Abstract available


  231. ABDULLAH KG, Bird CE, Buehler JD, Gattie LC, et al
    Establishment of patient-derived organoid models of lower grade glioma.
    Neuro Oncol. 2021 Nov 26. pii: 6444299. doi: 10.1093.
    PubMed     Abstract available


  232. CHIOCCA EA, Gelb AB, Chen CC, Rao G, et al
    Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial.
    Neuro Oncol. 2021 Nov 26. pii: 6444298. doi: 10.1093.
    PubMed     Abstract available


  233. DA COSTA ROSA M, Yamashita AS, Riggins GJ
    Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
    Neuro Oncol. 2021 Nov 26. pii: 6440681. doi: 10.1093.
    PubMed     Abstract available


  234. DE JOODE K, Taal W, Snijders TJ, Hanse M, et al
    Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.
    Neuro Oncol. 2021 Nov 24. pii: 6437945. doi: 10.1093.
    PubMed    


  235. KIELISZEK AM, Aghaei N, Bassey-Archibong B, Singh SK, et al
    Low and steady wins the race: for melanoma-brain metastases, is prevention better than a cure?
    Neuro Oncol. 2021 Nov 24. pii: 6438512. doi: 10.1093.
    PubMed    


  236. WU J
    Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
    Neuro Oncol. 2021 Nov 22. pii: 6433381. doi: 10.1093.
    PubMed    


  237. ALMSTEDT E, Rosen E, Gloger M, Stockgard R, et al
    Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
    Neuro Oncol. 2021 Nov 19. pii: 6432157. doi: 10.1093.
    PubMed     Abstract available


  238. NASSIRI F, Wang JZ, Au K, Barnholtz-Sloan J, et al
    Consensus core clinical data elements for meningiomas.
    Neuro Oncol. 2021 Nov 17. pii: 6430437. doi: 10.1093.
    PubMed     Abstract available


  239. BALIGA S, Gallotto S, Bajaj B, Lewy J, et al
    Decade Long Disease, Secondary Malignancy, and Brainstem Injury Outcomes in Pediatric and Young Adult Medulloblastoma Patients Treated with Proton Radiotherapy.
    Neuro Oncol. 2021 Nov 12. pii: 6425899. doi: 10.1093.
    PubMed     Abstract available


  240. KACHURI L, Walsh KM
    Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma.
    Neuro Oncol. 2021 Nov 10. pii: 6425113. doi: 10.1093.
    PubMed    


  241. ELLINGSON BM, Kim GHJ, Brown M, Lee J, et al
    Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.
    Neuro Oncol. 2021 Nov 9. pii: 6424025. doi: 10.1093.
    PubMed     Abstract available


  242. ARAKAKI AKS, Szulzewsky F, Gilbert MR, Gujral TS, et al
    Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  243. PRATT D, Sahm F, Aldape K
    DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  244. ARMSTRONG TS, Gilbert MR
    Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  245. PENAS-PRADO M
    Rare central nervous system tumors: the path to progress.
    Neuro Oncol. 2021;23.
    PubMed    


  246. ASA SL, Mete O
    Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies.
    Neuro Oncol. 2021;23:1803-1804.
    PubMed    


  247. CUI Y, Li C, Jiang Z, Zhang S, et al
    Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
    Neuro Oncol. 2021;23:1859-1871.
    PubMed     Abstract available


    October 2021
  248. MOLINARO AM
    External Controls to Improve on Glioblastoma Clinical Trials.
    Neuro Oncol. 2021 Oct 29. pii: 6414401. doi: 10.1093.
    PubMed    


  249. ANDREWS LJ, Thornton ZA, Saincher SS, Yao IY, et al
    Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Neuro Oncol. 2021 Oct 28. pii: 6413773. doi: 10.1093.
    PubMed     Abstract available


  250. SCHWARTZBAUM J, Harris R
    Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival.
    Neuro Oncol. 2021 Oct 25. pii: 6409990. doi: 10.1093.
    PubMed    


  251. VACHHA BA, Huang RY
    BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas.
    Neuro Oncol. 2021 Oct 25. pii: 6409977. doi: 10.1093.
    PubMed    


  252. PREUSSER M, Silvani A, Le Rhun E, Soffietti R, et al
    Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
    Neuro Oncol. 2021 Oct 21. pii: 6406919. doi: 10.1093.
    PubMed     Abstract available


  253. BARRETTE AM, Ronk H, Joshi T, Mussa Z, et al
    Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models.
    Neuro Oncol. 2021 Oct 17. pii: 6398692. doi: 10.1093.
    PubMed     Abstract available


  254. CLUCERU J, Interian Y, Phillips JJ, Molinaro AM, et al
    Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
    Neuro Oncol. 2021 Oct 15. pii: 6398212. doi: 10.1093.
    PubMed     Abstract available


  255. PANT A, Lim M
    Checkpoint blockade in recurrent meningiomas: Lessons for future management.
    Neuro Oncol. 2021 Oct 9. pii: 6385431. doi: 10.1093.
    PubMed    


  256. HOOGSTRATE Y, Ghisai SA, de Wit M, de Heer I, et al
    The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis.
    Neuro Oncol. 2021 Oct 5. pii: 6381406. doi: 10.1093.
    PubMed     Abstract available


  257. OSTROM QT, Cioffi G, Waite K, Kruchko C, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  258. STROWD RE
    Etched in Code: Revisiting glioma risk factors through the exome.
    Neuro Oncol. 2021 Oct 4. pii: 6380799. doi: 10.1093.
    PubMed    


  259. FRIEDMAN GK, Dhall G
    Potential Role of Carbon Ion Radiotherapy in Chromothripsis-induced Medulloblastoma and Other Malignancies.
    Neuro Oncol. 2021 Oct 4. pii: 6380754. doi: 10.1093.
    PubMed    


  260. WU J, Gupta R, Barreto J, Doo P, et al
    Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.
    Neuro Oncol. 2021;23:1798-1800.
    PubMed    


  261. PERTZ M, Schlegel U
    Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?
    Neuro Oncol. 2021;23:1623-1624.
    PubMed    


  262. MILDE T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, et al
    Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.
    Neuro Oncol. 2021;23:1634-1646.
    PubMed     Abstract available


  263. GENG H, Tsang M, Subbaraj L, Cleveland J, et al
    Tumor metabolism and neurocognition in CNS lymphoma.
    Neuro Oncol. 2021;23:1668-1679.
    PubMed     Abstract available


    September 2021
  264. DEL BENE M, Osti D, Faletti S, Beznousenko GV, et al
    Extracellular vesicles: the key for precision medicine in glioblastoma.
    Neuro Oncol. 2021 Sep 28. pii: 6377304. doi: 10.1093.
    PubMed     Abstract available


  265. RAO R, Han R, Ogurek S, Xue C, et al
    Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition.
    Neuro Oncol. 2021 Sep 25. pii: 6375369. doi: 10.1093.
    PubMed     Abstract available


  266. PENG J, Kim DD, Patel JB, Zeng X, et al
    Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
    Neuro Oncol. 2021 Sep 22. pii: 6374130. doi: 10.1093.
    PubMed    


  267. JOSEPH JV, Magaut CR, Storevik S, Geraldo LH, et al
    TGF- promotes microtube formation in glioblastoma through Thrombospondin 1.
    Neuro Oncol. 2021 Sep 20. pii: 6372853. doi: 10.1093.
    PubMed     Abstract available


  268. LUCAS CG, Mueller S, Reddy A, Taylor JW, et al
    Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Neuro Oncol. 2021 Sep 14. pii: 6370137. doi: 10.1093.
    PubMed    


  269. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Sep 14. pii: 6370123. doi: 10.1093.
    PubMed    


  270. BORNHORST M
    New insights into low grade glioma tumor microenvironment for improved patient management.
    Neuro Oncol. 2021 Sep 13. pii: 6369407. doi: 10.1093.
    PubMed    


  271. ABOUNADER R, Schiff D
    The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma.
    Neuro Oncol. 2021 Sep 13. pii: 6369406. doi: 10.1093.
    PubMed    


  272. ZHANG W, Talele S, Sarkaria JN, Elmquist WF, et al
    Changes in the vasculature of human brain tumors: Implications for treatment.
    Neuro Oncol. 2021 Sep 13. pii: 6369378. doi: 10.1093.
    PubMed    


  273. IJARE OB, Hambarde S, Brasil da Costa FH, Lopez S, et al
    Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
    Neuro Oncol. 2021 Sep 13. pii: 6369334. doi: 10.1093.
    PubMed     Abstract available


  274. MAROSI C
    Will mastering ferroptosis allow treating refractory meningiomas?
    Neuro Oncol. 2021 Sep 13. pii: 6369228. doi: 10.1093.
    PubMed    


  275. DRIVER J, Hoffman SE, Tavakol S, Woodward E, et al
    A Molecularly Integrated Grade for Meningioma.
    Neuro Oncol. 2021 Sep 11. pii: 6368844. doi: 10.1093.
    PubMed     Abstract available


  276. TOM MC, Kotecha R
    Beating a Benchmark: Boron Neutron Capture Therapy for Recurrent and Refractory Meningiomas.
    Neuro Oncol. 2021 Sep 11. pii: 6368846. doi: 10.1093.
    PubMed    


  277. IUS T, Ng S, Young JS, Tomasino B, et al
    The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study.
    Neuro Oncol. 2021 Sep 8. pii: 6366593. doi: 10.1093.
    PubMed     Abstract available


  278. SAUNDERS CN, Kinnersley B, Culliford R, Cornish AJ, et al
    Relationship between genetically determined telomere length and glioma risk.
    Neuro Oncol. 2021 Sep 3. pii: 6363706. doi: 10.1093.
    PubMed     Abstract available


  279. WANG D, Veo B, Pierce A, Fosmire S, et al
    A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Neuro Oncol. 2021 Sep 3. pii: 6363671. doi: 10.1093.
    PubMed     Abstract available


  280. BANDOPADHAYAY P, Chi SN
    The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
    Neuro Oncol. 2021 Sep 3. pii: 6363655. doi: 10.1093.
    PubMed    


  281. AQUILANTI E, Kageler L, Wen PY, Meyerson M, et al
    Telomerase as a therapeutic target in glioblastoma.
    Neuro Oncol. 2021 Sep 2. pii: 6362724. doi: 10.1093.
    PubMed     Abstract available


  282. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Neuro Oncol. 2021;23:1457-1469.
    PubMed     Abstract available


  283. THACKER N, Bouffet E
    Posterior fossa syndrome-time to unmute the silence on cerebellar mutism.
    Neuro Oncol. 2021;23:1427-1428.
    PubMed    


  284. VON HOFF K, Haberler C, Schmitt-Hoffner F, Schepke E, et al
    Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.
    Neuro Oncol. 2021;23:1597-1611.
    PubMed     Abstract available


  285. KHAN RB, Patay Z, Klimo P, Huang J, et al
    Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study.
    Neuro Oncol. 2021;23:1586-1596.
    PubMed     Abstract available


    August 2021
  286. CHUNG C, Brown PD, Wefel JS
    Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al.
    Neuro Oncol. 2021 Aug 28. pii: 6359127. doi: 10.1093.
    PubMed    


  287. PRESS RH, Chhabra AM, Choi JI, Hasan S, et al
    Proton therapy for newly diagnosed glioblastoma: more room for investigation.
    Neuro Oncol. 2021 Aug 28. pii: 6359128. doi: 10.1093.
    PubMed    


  288. CICONE F, Cascini GL, Minniti G
    Reply to: "Letter to the Editor: Assessment of imaging biomarkers in the follow-up of brain metastases after SRS".
    Neuro Oncol. 2021 Aug 24. pii: 6357080. doi: 10.1093.
    PubMed    


  289. DERKS SHAE, Jongen JLM, van den Bent MJ, van der Veldt AAM, et al
    Assessment of imaging biomarkers in the follow-up of brain metastases after SRS.
    Neuro Oncol. 2021 Aug 24. pii: 6357079. doi: 10.1093.
    PubMed    


  290. RONSLEY R, Bouffet E
    COVID-19 in pediatric cancer: Where are the brain tumors?
    Neuro Oncol. 2021 Aug 20. pii: 6355395. doi: 10.1093.
    PubMed    


  291. WANG GM, Cioffi G, Patil N, Waite KA, et al
    Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
    Neuro Oncol. 2021 Aug 13. pii: 6350590. doi: 10.1093.
    PubMed     Abstract available


  292. JO J, Donahue J, Sarai G, Petroni G, et al
    Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk?
    Neuro Oncol. 2021 Aug 12. pii: 6348905. doi: 10.1093.
    PubMed     Abstract available


  293. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
    Neuro Oncol. 2021 Aug 7. pii: 6345198. doi: 10.1093.
    PubMed    


  294. LAMBA N, Aizer AA
    The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.
    Neuro Oncol. 2021 Aug 5. pii: 6341089. doi: 10.1093.
    PubMed    


  295. WINKLER F
    Silencing glioblastoma networks to make temozolomide more effective.
    Neuro Oncol. 2021 Aug 4. pii: 6339977. doi: 10.1093.
    PubMed    


  296. SU JM, Kilburn LB, Mansur DB, Krailo M, et al
    Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
    Neuro Oncol. 2021 Aug 4. pii: 6339987. doi: 10.1093.
    PubMed     Abstract available


  297. HUANG H, Georganaki M, Conze LL, Lavina B, et al
    ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
    Neuro Oncol. 2021 Aug 4. pii: 6339962. doi: 10.1093.
    PubMed     Abstract available


  298. WEN PY, Packer RJ
    The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications.
    Neuro Oncol. 2021;23:1215-1217.
    PubMed    


  299. LOUIS DN, Perry A, Wesseling P, Brat DJ, et al
    The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Neuro Oncol. 2021;23:1231-1251.
    PubMed     Abstract available


  300. CORREA DD
    Neurocognitive functions in primary CNS lymphoma.
    Neuro Oncol. 2021;23:1220-1221.
    PubMed    


  301. MOSELLA MS, Sabedot TS, Silva TC, Malta TM, et al
    DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
    Neuro Oncol. 2021;23:1292-1303.
    PubMed     Abstract available


  302. VAN DER MEULEN M, Dirven L, Habets EJJ, Bakunina K, et al
    Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
    Neuro Oncol. 2021;23:1315-1326.
    PubMed     Abstract available


    July 2021
  303. MUNOZ PINTO MF, Campbell SJ, Simoglou Karali C, Johanssen VA, et al
    Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.
    Neuro Oncol. 2021 Jul 23. pii: 6326734. doi: 10.1093.
    PubMed     Abstract available


  304. RICHARDSON S, Hill RM, Kui C, Lindsey JC, et al
    Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
    Neuro Oncol. 2021 Jul 17. pii: 6323243. doi: 10.1093.
    PubMed     Abstract available


  305. SHIH HA
    An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
    Neuro Oncol. 2021 Jul 16. pii: 6323026. doi: 10.1093.
    PubMed    


  306. HULSBERGEN AFC, Abunimer AM, Ida F, Kavouridis VK, et al
    Neurosurgical resection for locally recurrent brain metastasis.
    Neuro Oncol. 2021 Jul 16. pii: 6322695. doi: 10.1093.
    PubMed     Abstract available


  307. SHARMA P, Xu J, Williams K, Easley M, et al
    Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Neuro Oncol. 2021 Jul 14. pii: 6321319. doi: 10.1093.
    PubMed     Abstract available


  308. LUDWIG N, Rao A, Sandlesh P, Yerneni SS, et al
    Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
    Neuro Oncol. 2021 Jul 13. pii: 6320007. doi: 10.1093.
    PubMed     Abstract available


  309. RAMASWAMY V, Bartels U
    Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
    Neuro Oncol. 2021 Jul 12. pii: 6319139. doi: 10.1093.
    PubMed    


  310. BALANA C, Sun C, Vaz MA, Esteve A, et al
    Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318238. doi: 10.1093.
    PubMed    


  311. TERABE M, Wu J
    Rethinking Immunotherapy in Meningiomas.
    Neuro Oncol. 2021 Jul 9. pii: 6318447. doi: 10.1093.
    PubMed    


  312. ZHAO B, Ma W
    Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318242. doi: 10.1093.
    PubMed    


  313. BAGLEY SJ, Kline CN
    Understanding the global impact of primary brain tumors: the untapped potential of population-based cancer registries.
    Neuro Oncol. 2021 Jul 9. pii: 6318451. doi: 10.1093.
    PubMed    


  314. LUKAS RV
    Essential Oils for Blood-Brain Barrier Disruption: Preclinical Studies of NEO100 in Breast Cancer Brain Metastases.
    Neuro Oncol. 2021 Jul 9. pii: 6318449. doi: 10.1093.
    PubMed    


  315. ALHALABI OT, Fletcher MNC, Hielscher T, Kessler T, et al
    A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
    Neuro Oncol. 2021 Jul 7. pii: 6316731. doi: 10.1093.
    PubMed     Abstract available


  316. TONOGAI EJ, Huang S, Botham RC, Berry MR, et al
    Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
    Neuro Oncol. 2021 Jul 3. pii: 6314291. doi: 10.1093.
    PubMed     Abstract available


  317. TEHRANIAN C, Fankhauser L, Harter PN, Ratcliffe CDH, et al
    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
    Neuro Oncol. 2021 Jul 3. pii: 6314211. doi: 10.1093.
    PubMed     Abstract available


  318. PETRIDIS PD, Horenstein C, Pereira B, Wu P, et al
    BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
    Neuro Oncol. 2021 Jul 2. pii: 6313213. doi: 10.1093.
    PubMed     Abstract available


  319. YAMAZAKI S, Ohka F, Hirano M, Shiraki Y, et al
    Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
    Neuro Oncol. 2021 Jul 2. pii: 6313216. doi: 10.1093.
    PubMed     Abstract available


  320. D'ALESSANDRIS QG, Della Pepa GM, Noya C, Olivi A, et al
    Mesenchymal stem cells: are they the good or the bad?
    Neuro Oncol. 2021;23:1203-1204.
    PubMed    


  321. DANKNER M, Maritan SM
    The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.
    Neuro Oncol. 2021;23:1207.
    PubMed    


  322. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic factors in leptomeningeal metastases.
    Neuro Oncol. 2021;23:1208-1209.
    PubMed    


  323. BARAJAS RF, Politi LS, Anzalone N, Schoder H, et al
    Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
    Neuro Oncol. 2021;23:1056-1071.
    PubMed     Abstract available


  324. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
    Neuro Oncol. 2021;23:1100-1112.
    PubMed     Abstract available


  325. FORDE C, King AT, Rutherford SA, Hammerbeck-Ward C, et al
    Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
    Neuro Oncol. 2021;23:1113-1124.
    PubMed     Abstract available


    June 2021
  326. GOLDBRUNNER R, Stavrinou P, Jenkinson MD, Sahm F, et al
    EANO guideline on the diagnosis and management of meningiomas.
    Neuro Oncol. 2021 Jun 28. pii: 6310843. doi: 10.1093.
    PubMed     Abstract available


  327. WALBERT T, Harrison RA, Schiff D, Avila EK, et al
    SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310125. doi: 10.1093.
    PubMed     Abstract available


  328. PENG J, Kim DD, Patel JB, Zeng X, et al
    Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310123. doi: 10.1093.
    PubMed     Abstract available


  329. WIRSCHING HG, Steiner L, Becker D, Regli L, et al
    Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression.
    Neuro Oncol. 2021 Jun 19. pii: 6305986. doi: 10.1093.
    PubMed    


  330. JOHNSON KC, Verhaak RGW
    Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring.
    Neuro Oncol. 2021 Jun 17. pii: 6302547. doi: 10.1093.
    PubMed    


  331. HAU P
    Dissecting adult SHH-activated medulloblastoma - molecularly defined tumor subsets reveal new prognostic biomarkers.
    Neuro Oncol. 2021 Jun 17. pii: 6302543. doi: 10.1093.
    PubMed    


  332. SHAH AH, Gilbert M, Ivan ME, Komotar RJ, et al
    The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.
    Neuro Oncol. 2021 Jun 12. pii: 6297568. doi: 10.1093.
    PubMed     Abstract available


  333. ERKER C, Lane A, Chaney B, Leary S, et al
    Characteristics of Patients >/= 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry.
    Neuro Oncol. 2021 Jun 11. pii: 6296498. doi: 10.1093.
    PubMed     Abstract available


  334. SHEEHAN J, Pikis S, Islim A, Chen CJ, et al
    An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Stereotactic Radiosurgery: The IMPASSE Study.
    Neuro Oncol. 2021 Jun 9. pii: 6295369. doi: 10.1093.
    PubMed     Abstract available


  335. KOTECHA R, Aboian M, Nabavizadeh SA, Parent EE, et al
    Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291736. doi: 10.1093.
    PubMed    


  336. GALLDIKS N, Niyazi M, Tonn JC, Langen KJ, et al
    Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291737. doi: 10.1093.
    PubMed    


  337. RIEMONDY KA, Venkataraman S, Willard N, Nellan A, et al
    Neoplastic and immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
    Neuro Oncol. 2021 Jun 2. pii: 6291352. doi: 10.1093.
    PubMed     Abstract available


  338. RITZMANN TA, Kilday JP, Grundy RG
    Pediatric ependymomas: destined to recur?
    Neuro Oncol. 2021;23:874-876.
    PubMed    


  339. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States.
    Neuro Oncol. 2021;23:979-989.
    PubMed     Abstract available


  340. ADOLPH JE, Fleischhack G, Mikasch R, Zeller J, et al
    Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
    Neuro Oncol. 2021;23:1012-1023.
    PubMed     Abstract available


    May 2021
  341. PHILLIPS LM, Li S, Gumin J, Daou M, et al
    An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Neuro Oncol. 2021 May 31. pii: 6290257. doi: 10.1093.
    PubMed     Abstract available


  342. MARIN BM, Porath KA, Jain S, Kim M, et al
    Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Neuro Oncol. 2021 May 29. pii: 6288409. doi: 10.1093.
    PubMed     Abstract available


  343. SCOCCIANTI S, Olmetto E, Pinzi V, Osti MF, et al
    Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
    Neuro Oncol. 2021 May 29. pii: 6288399. doi: 10.1093.
    PubMed     Abstract available


  344. VERBURG N, Barthel FP, Anderson KJ, Johnson KC, et al
    Spatial concordance of DNA methylation classification in diffuse glioma.
    Neuro Oncol. 2021 May 28. pii: 6287958. doi: 10.1093.
    PubMed     Abstract available


  345. SIMOVIC M, Bolkestein M, Moustafa M, Wong JKL, et al
    Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
    Neuro Oncol. 2021 May 28. pii: 6287957. doi: 10.1093.
    PubMed     Abstract available


  346. DE ANDRADE COSTA A, Chatterjee J, Cobb O, Sanapala S, et al
    RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.
    Neuro Oncol. 2021 May 27. pii: 6286081. doi: 10.1093.
    PubMed     Abstract available


  347. LI Y, Wang X, Qi S, Gao L, et al
    Spliceosome-regulated RSRP1-dependent NF-kappaB activation promotes the glioblastoma mesenchymal phenotype.
    Neuro Oncol. 2021 May 27. pii: 6286882. doi: 10.1093.
    PubMed     Abstract available


  348. LAPERRIERE NJ
    Protons for the Management of Adult Patients with Glioblastoma.
    Neuro Oncol. 2021 May 24. pii: 6283746. doi: 10.1093.
    PubMed    


  349. MENDOZA TR
    Especially for neuro-oncologists - minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 May 24. pii: 6283743. doi: 10.1093.
    PubMed    


  350. CHONGSATHIDKIET P, Fecci PE
    Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases.
    Neuro Oncol. 2021 May 24. pii: 6283744. doi: 10.1093.
    PubMed    


  351. BI WL, Nayak L, Meredith DM, Driver J, et al
    Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
    Neuro Oncol. 2021 May 20. pii: 6279078. doi: 10.1093.
    PubMed     Abstract available


  352. GUSYATINER O, Bady P, Pham MDT, Lei Y, et al
    BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
    Neuro Oncol. 2021 May 14. pii: 6275457. doi: 10.1093.
    PubMed     Abstract available


  353. SIM HW, McDonald KL, Lwin Z, Barnes EH, et al
    A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
    Neuro Oncol. 2021 May 13. pii: 6275307. doi: 10.1093.
    PubMed     Abstract available


  354. DAHL NA, Vibhakar R
    Converging evidence for inhibition of transcriptional control in high-grade gliomas.
    Neuro Oncol. 2021 May 13. pii: 6275360. doi: 10.1093.
    PubMed    


  355. TAKAI S, Wanibuchi M, Kawabata S, Takeuchi K, et al
    Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
    Neuro Oncol. 2021 May 13. pii: 6275296. doi: 10.1093.
    PubMed     Abstract available


  356. BAO Z, Hua L, Ye Y, Wang D, et al
    MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
    Neuro Oncol. 2021 May 13. pii: 6275374. doi: 10.1093.
    PubMed     Abstract available


  357. WANG Z, Gao L, Wang Y, Chang M, et al
    Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma.
    Neuro Oncol. 2021 May 13. pii: 6275034. doi: 10.1093.
    PubMed    


  358. NASSIRI F, Wang JZ, Singh O, Karimi S, et al
    Loss of H3K27me3 in meningiomas.
    Neuro Oncol. 2021 May 10. pii: 6273127. doi: 10.1093.
    PubMed     Abstract available


  359. FELKER J, Agnihotri S
    Not all mouse blood-brain barriers are created equal.
    Neuro Oncol. 2021;23:705-706.
    PubMed    


  360. SO J, Mamatjan Y, Zadeh G, Aldape K, et al
    Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.
    Neuro Oncol. 2021;23:795-802.
    PubMed     Abstract available


  361. MASSIMINO M, Barretta F, Modena P, Witt H, et al
    Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
    Neuro Oncol. 2021;23:848-857.
    PubMed     Abstract available


  362. CLAUS EB, Cannataro VL, Gaffney SG, Townsend JP, et al
    Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2021 May 4. pii: 6263733. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  363. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.
    Neuro Oncol. 2021 Apr 30. pii: 6263562. doi: 10.1093.
    PubMed     Abstract available


  364. YEUNG J, Yaghoobi V, Miyagishima D, Vesely MD, et al
    Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.
    Neuro Oncol. 2021 Apr 29. pii: 6259024. doi: 10.1093.
    PubMed     Abstract available


  365. TESILEANU CMS, van den Bent MJ, Sanson M, Wick W, et al
    Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Neuro Oncol. 2021 Apr 29. pii: 6259004. doi: 10.1093.
    PubMed     Abstract available


  366. LAMBA N, Wen PY, Aizer AA
    Epidemiology of Brain Metastases and Leptomeningeal Disease.
    Neuro Oncol. 2021 Apr 28. pii: 6256866. doi: 10.1093.
    PubMed     Abstract available


  367. STROTHER D, Lafay-Cousin L
    Adjuvant therapy for high risk medulloblastoma: More is better?
    Neuro Oncol. 2021 Apr 27. pii: 6254485. doi: 10.1093.
    PubMed    


  368. MARINELLI JP, Carlson ML
    Potential for selection bias surrounding reporting of benign brain tumors in the United States.
    Neuro Oncol. 2021 Apr 26. pii: 6253739. doi: 10.1093.
    PubMed    


  369. TAWBI HA, Forsyth PA, Hodi FS, Lao CD, et al
    Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
    Neuro Oncol. 2021 Apr 21. pii: 6242717. doi: 10.1093.
    PubMed     Abstract available


  370. NICLOU SP, Golebiewska A
    Turning strength into weakness: protein degradation and autophagy as therapeutic targets in Glioblastoma?
    Neuro Oncol. 2021 Apr 17. pii: 6231737. doi: 10.1093.
    PubMed    


  371. SCHNEIDER M, Vollmer L, Potthoff AL, Ravi VM, et al
    Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
    Neuro Oncol. 2021 Apr 17. pii: 6231712. doi: 10.1093.
    PubMed     Abstract available


  372. VISWANATH P, Batsios G, Ayyappan V, Taglang C, et al
    Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
    Neuro Oncol. 2021 Apr 17. pii: 6231711. doi: 10.1093.
    PubMed     Abstract available


  373. VOLMAR MNM, Cheng J, Alenezi H, Richter S, et al
    Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties.
    Neuro Oncol. 2021 Apr 17. pii: 6231710. doi: 10.1093.
    PubMed     Abstract available


  374. KATSUSHIMA K, Lee B, Kunhiraman H, Zhong C, et al
    The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas.
    Neuro Oncol. 2021;23:572-585.
    PubMed     Abstract available


  375. THOMAS C, Soschinski P, Zwaig M, Oikonomopoulos S, et al
    The genetic landscape of choroid plexus tumors in children and adults.
    Neuro Oncol. 2021;23:650-660.
    PubMed     Abstract available


  376. WANIS HA, Moller H, Ashkan K, Davies EA, et al
    The incidence of major subtypes of primary brain tumours in adults in England 1995-2017.
    Neuro Oncol. 2021 Apr 9. pii: 6218679. doi: 10.1093.
    PubMed     Abstract available


  377. HORBINSKI C, McCortney K, Stupp R
    MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 8. pii: 6217333. doi: 10.1093.
    PubMed    


  378. MUKHERJEE S, Schiltz G, Clutter M, Mishra R, et al
    Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS.
    Neuro Oncol. 2021 Apr 7. pii: 6214067. doi: 10.1093.
    PubMed    


  379. MUKHERJEE S, Olson C, Dundar B, Sharma N, et al
    Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS.
    Neuro Oncol. 2021 Apr 7. pii: 6214066. doi: 10.1093.
    PubMed    


  380. FRAPPAZ D, Barritault M, Montane L, Laigle-Donadey F, et al
    MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Neuro Oncol. 2021 Apr 7. pii: 6213882. doi: 10.1093.
    PubMed     Abstract available


  381. YU Y, Villanueva-Meyer J, Grimmer MR, Hilz S, et al
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 5. pii: 6211336. doi: 10.1093.
    PubMed     Abstract available


  382. SANTAGATA S, Ligon KL
    Prognostication for meningiomas: H3K27me3 to the rescue?
    Neuro Oncol. 2021 Apr 3. pii: 6209863. doi: 10.1093.
    PubMed    


  383. TSANG DS, Schulte F
    Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship.
    Neuro Oncol. 2021 Apr 3. pii: 6209877. doi: 10.1093.
    PubMed    


  384. LEE EQ, Selig W, Meehan C, Bacha J, et al
    Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
    Neuro Oncol. 2021 Apr 2. pii: 6209406. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  385. PERKINS S, Acharya S
    Radiation therapy to the developing brain: advanced technology is ready for robust optimization parameters.
    Neuro Oncol. 2021;23:350-351.
    PubMed    


  386. LASSMAN AB, Cloughesy TF
    Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
    Neuro Oncol. 2021;23:347-349.
    PubMed    


  387. KUMTHEKAR P, Dunbar EM, Peters KB, Brastianos PK, et al
    A broad perspective on evaluating bias in the neuro-oncology workplace.
    Neuro Oncol. 2021;23:498-499.
    PubMed    


  388. GILBERT MR, Yuan Y, Wu J, Mendoza T, et al
    A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
    Neuro Oncol. 2021;23:468-477.
    PubMed     Abstract available


  389. JAECKLE KA, Ballman KV, van den Bent M, Giannini C, et al
    CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
    Neuro Oncol. 2021;23:457-467.
    PubMed     Abstract available


  390. BOURDEAUT F
    Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?
    Neuro Oncol. 2021 Mar 23. pii: 6182498. doi: 10.1093.
    PubMed    


  391. LU SL, Xiao FR, Cheng JC, Yang WC, et al
    Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.
    Neuro Oncol. 2021 Mar 23. pii: 6180141. doi: 10.1093.
    PubMed     Abstract available


  392. LATHIA JD
    Fountain of chaos: cerebrospinal fluid enhancement of cancer stem cells in glioblastoma.
    Neuro Oncol. 2021 Mar 22. pii: 6179836. doi: 10.1093.
    PubMed    


  393. NOBRE L, Ramaswamy V
    Medulloblastoma (cross)talk through extracellular vesicles.
    Neuro Oncol. 2021 Mar 22. pii: 6179837. doi: 10.1093.
    PubMed    


  394. OSTROM QT, Edelson J, Byun J, Han Y, et al
    Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
    Neuro Oncol. 2021 Mar 20. pii: 6179266. doi: 10.1093.
    PubMed     Abstract available


  395. GIRARDI F, Rous B, Stiller CA, Gatta G, et al
    The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
    Neuro Oncol. 2021 Mar 19. pii: 6178525. doi: 10.1093.
    PubMed     Abstract available


  396. VERKOUTEREN BJA, Cosgun B, Vermeulen RJ, Reinders MGHC, et al
    Prevalence of medulloblastoma in basal cell nevus syndrome patients with a PTCH1 mutation.
    Neuro Oncol. 2021 Mar 17. pii: 6231902. doi: 10.1093.
    PubMed    


  397. TSIEN C
    Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?
    Neuro Oncol. 2021 Mar 12. pii: 6168946. doi: 10.1093.
    PubMed    


  398. WINKLER F
    In glioma, all endothelial cells are not created the same.
    Neuro Oncol. 2021 Mar 11. pii: 6168415. doi: 10.1093.
    PubMed    


  399. SAIT SF, Karajannis MA
    Pediatric spinal cord gliomas - low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?
    Neuro Oncol. 2021 Mar 11. pii: 6168346. doi: 10.1093.
    PubMed    


  400. TRIFILETTI DM, Brown PD
    Cognitive outcomes in patients with low-grade glioma.
    Neuro Oncol. 2021 Mar 11. pii: 6168225. doi: 10.1093.
    PubMed    


  401. FONSECA A, Bouffet E
    Brainstem Gliomas... The Devil is in the Details.
    Neuro Oncol. 2021 Mar 11. pii: 6168340. doi: 10.1093.
    PubMed    


  402. BAUMERT BG, Pesce GA
    Elderly patients with brain metastases: new support for the balancing act in treatment decision making.
    Neuro Oncol. 2021 Mar 11. pii: 6168221. doi: 10.1093.
    PubMed    


  403. MENG Y, Pople CB, Suppiah S, Llinas M, et al
    MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
    Neuro Oncol. 2021 Mar 10. pii: 6167330. doi: 10.1093.
    PubMed     Abstract available


  404. LIM-FAT MJ, Maralani PJ
    Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy?
    Neuro Oncol. 2021 Mar 1. pii: 6155531. doi: 10.1093.
    PubMed    


  405. SPERDUTO PW, Lou E
    The Past, Current and Future Management of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
    Neuro Oncol. 2021 Mar 1. pii: 6155599. doi: 10.1093.
    PubMed    


    February 2021
  406. GIANNINI C, Giangaspero F
    TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma?
    Neuro Oncol. 2021 Feb 28. pii: 6154503. doi: 10.1093.
    PubMed    


  407. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Feb 28. pii: 6154448. doi: 10.1093.
    PubMed     Abstract available


  408. BROWN PD, Chung C, Liu DD, McAvoy S, et al
    A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2021 Feb 27. pii: 6154000. doi: 10.1093.
    PubMed     Abstract available


  409. JESSURUN CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, et al
    The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
    Neuro Oncol. 2021 Feb 25. pii: 6150018. doi: 10.1093.
    PubMed     Abstract available


  410. FANGUSARO J, Onar-Thomas A, Poussaint TY, Wu S, et al
    A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2021 Feb 25. pii: 6149924. doi: 10.1093.
    PubMed     Abstract available


  411. TSCHERNICHOVSKY R, Katz LH, Derazne E, Berliner MB, et al
    Height in Adolescence as a Risk Factor for Glioma Subtypes: a Nationwide Retrospective Cohort Study of 2.2 Million Subjects.
    Neuro Oncol. 2021 Feb 25. pii: 6149925. doi: 10.1093.
    PubMed     Abstract available


  412. JAIN R, Chi AS
    Radiogenomics identifying important biological pathways in gliomas.
    Neuro Oncol. 2021;23:177-178.
    PubMed    


  413. ELLINGSON BM, Brown MS, Boxerman JL, Gerstner ER, et al
    Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
    Neuro Oncol. 2021;23:189-198.
    PubMed     Abstract available


  414. KANAMORI M, Takami H, Yamaguchi S, Sasayama T, et al
    So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?
    Neuro Oncol. 2021;23:295-303.
    PubMed     Abstract available


  415. CANNON-ALBRIGHT LA, Farnham JM, Stevens J, Teerlink CC, et al
    Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.
    Neuro Oncol. 2021;23:277-283.
    PubMed     Abstract available


  416. MATHEN P, Smart DK
    Reimagining External Beam Radiotherapy for Glioblastoma: "Old Beam, New Trick".
    Neuro Oncol. 2021 Feb 22. pii: 6146614. doi: 10.1093.
    PubMed    


  417. KIM MM, Aryal MP, Sun Y, Parmar HA, et al
    Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2021 Feb 18. pii: 6144576. doi: 10.1093.
    PubMed     Abstract available


  418. DIRVEN L, Musoro JZ, Coens C, Reijneveld JC, et al
    Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 Feb 18. pii: 6142946. doi: 10.1093.
    PubMed     Abstract available


  419. KORSHUNOV A, Okonechnikov K, Stichel D, Ryzhova M, et al
    Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
    Neuro Oncol. 2021 Feb 16. pii: 6137557. doi: 10.1093.
    PubMed     Abstract available


  420. HUANG T, Cheng SY
    Targeting phospholipid metabolism for glioblastoma therapy.
    Neuro Oncol. 2021 Feb 9. pii: 6131652. doi: 10.1093.
    PubMed    


  421. SCHAFFENRATH J, Wyss T, He L, Rushing EJ, et al
    Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.
    Neuro Oncol. 2021 Feb 9. pii: 6131739. doi: 10.1093.
    PubMed     Abstract available


  422. SABEDOT T, Malta T, Snyder J, Nelson K, et al
    A serum-based DNA methylation assay provides accurate detection of glioma.
    Neuro Oncol. 2021 Feb 9. pii: 6131768. doi: 10.1093.
    PubMed     Abstract available


  423. GRAILLON T, Ferrer L, Siffre J, Sanson M, et al
    Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
    Neuro Oncol. 2021 Feb 8. pii: 6131353. doi: 10.1093.
    PubMed     Abstract available


  424. GUO X, Wang S, Wang Y, Ma W, et al
    Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131355. doi: 10.1093.
    PubMed    


  425. YAMAMOTO M, Sanomachi T, Suzuki S, Uchida H, et al
    Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
    Neuro Oncol. 2021 Feb 8. pii: 6131352. doi: 10.1093.
    PubMed     Abstract available


  426. OTANI Y, Sur H, Rachaiah G, Namagiri S, et al
    Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131351. doi: 10.1093.
    PubMed     Abstract available


  427. TORRES VA, Ashford JM, Wright E, Xu J, et al
    The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial.
    Neuro Oncol. 2021 Feb 5. pii: 6128895. doi: 10.1093.
    PubMed     Abstract available


  428. LIAO Y, Luo Z, Deng Y, Zhang F, et al
    OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Neuro Oncol. 2021 Feb 4. pii: 6128721. doi: 10.1093.
    PubMed     Abstract available


  429. GALLDIKS N, Niyazi M, Grosu AL, Kocher M, et al
    Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
    Neuro Oncol. 2021 Feb 4. pii: 6128548. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  430. WEFEL JS, Armstrong TS, Pugh SL, Gilbert MR, et al
    Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).
    Neuro Oncol. 2021 Jan 30. pii: 6124000. doi: 10.1093.
    PubMed     Abstract available


  431. YANG TJ, Wijetunga NA, Yamada J, Wolden S, et al
    Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
    Neuro Oncol. 2021;23:134-143.
    PubMed     Abstract available


  432. NARITA Y, Nagane M, Mishima K, Terui Y, et al
    Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Neuro Oncol. 2021;23:122-133.
    PubMed     Abstract available


  433. MAIRE CL, Fuh MM, Kaulich K, Fita KD, et al
    Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification.
    Neuro Oncol. 2021 Jan 28. pii: 6122789. doi: 10.1093.
    PubMed     Abstract available


  434. GERRITSEN JKW, Vincent AJPE, De Vleeschouwer S
    Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome.
    Neuro Oncol. 2021 Jan 20. pii: 6104892. doi: 10.1093.
    PubMed    


  435. VARGAS LOPEZ AJ
    Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
    Neuro Oncol. 2021 Jan 20. pii: 6104916. doi: 10.1093.
    PubMed    


  436. DIAMANDIS P
    De-coding group 3 medulloblastoma biology with non-coding RNA.
    Neuro Oncol. 2021 Jan 20. pii: 6104902. doi: 10.1093.
    PubMed    


  437. KATAGI H, Takata N, Aoi Y, Zhang Y, et al
    Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2021 Jan 20. pii: 6104638. doi: 10.1093.
    PubMed     Abstract available


  438. WEN PY, Weller M, Chiocca EA, Lim M, et al
    Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez.
    Neuro Oncol. 2021 Jan 20. pii: 6104896. doi: 10.1093.
    PubMed    


  439. FULTS DW
    Stemming the growth of pediatric gliomas through histone modification.
    Neuro Oncol. 2021 Jan 20. pii: 6104497. doi: 10.1093.
    PubMed    


  440. DMYTRIW AA, Huang RY
    In search of predictive and response markers in antiangiogenic therapy of glioblastoma.
    Neuro Oncol. 2021 Jan 20. pii: 6104491. doi: 10.1093.
    PubMed    


  441. DANKNER M, Caron M, Al-Saadi T, Yu W, et al
    Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.
    Neuro Oncol. 2021 Jan 12. pii: 6089125. doi: 10.1093.
    PubMed     Abstract available


  442. WU S, Li X, Gao F, de Groot JF, et al
    PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Neuro Oncol. 2021 Jan 12. pii: 6089123. doi: 10.1093.
    PubMed     Abstract available


  443. BENITEZ JA, Finlay D, Castanza A, Parisian AD, et al
    Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
    Neuro Oncol. 2021 Jan 11. pii: 6081306. doi: 10.1093.
    PubMed     Abstract available


  444. GUTMAN DC, Young RJ
    IDH glioma radiogenomics in the era of deep learning.
    Neuro Oncol. 2021 Jan 8. pii: 6068851. doi: 10.1093.
    PubMed    


  445. SNUDERL M
    Molecular classification and deconvolution of the immune microenvironment in glioblastoma.
    Neuro Oncol. 2021 Jan 4. pii: 6062458. doi: 10.1093.
    PubMed    


  446. SHOFUDA T, Kanemura Y
    HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Neuro Oncol. 2021 Jan 4. pii: 6062389. doi: 10.1093.
    PubMed    


    December 2020
  447. SHAHZAD U, Taccone MS, Kumar SA, Okura H, et al
    Modeling human brain tumours in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.
    Neuro Oncol. 2020 Dec 30. pii: 6055605. doi: 10.1093.
    PubMed     Abstract available


  448. DUFOUR C, Foulon S, Geoffray A, Masliah-Planchon J, et al
    Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.
    Neuro Oncol. 2020 Dec 30. pii: 6055191. doi: 10.1093.
    PubMed     Abstract available


  449. CHUNTOVA P, Chow F, Watchmaker P, Galvez M, et al
    Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
    Neuro Oncol. 2020 Dec 24. pii: 6047273. doi: 10.1093.
    PubMed     Abstract available


  450. BEHLING F, Fodi C, Gepfner-Tuma I, Kaltenbach K, et al
    H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort.
    Neuro Oncol. 2020 Dec 24. pii: 6046432. doi: 10.1093.
    PubMed     Abstract available


  451. KUKSIS M, Gao Y, Tran W, Hoey C, et al
    The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Neuro Oncol. 2020 Dec 23. pii: 6046194. doi: 10.1093.
    PubMed     Abstract available


  452. CARLSON JC, Cantu-Gutierrez M, Lozzi B, Huang-Hobbs E, et al
    Identification of diverse tumor endothelial cell populations in malignant glioma.
    Neuro Oncol. 2020 Dec 23. pii: 6046199. doi: 10.1093.
    PubMed     Abstract available


  453. PATIL N, Kelly ME, Yeboa DN, Buerki RA, et al
    Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017.
    Neuro Oncol. 2020 Dec 21. pii: 6042829. doi: 10.1093.
    PubMed     Abstract available


  454. PERWEIN T, Benesch M, Kandels D, Pietsch T, et al
    High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group.
    Neuro Oncol. 2020 Dec 21. pii: 6042812. doi: 10.1093.
    PubMed     Abstract available


  455. BERNHARDT D, Combs SE
    Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
    Neuro Oncol. 2020;22:1893.
    PubMed    


  456. YANG Z, Zhang Y, Li R, Yisikandaer A, et al
    Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
    Neuro Oncol. 2020 Dec 17. pii: 6040795. doi: 10.1093.
    PubMed     Abstract available


  457. LIU Y, Li Z, Zhang M, Zhou H, et al
    Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity.
    Neuro Oncol. 2020 Dec 16. pii: 6039055. doi: 10.1093.
    PubMed     Abstract available


  458. HAYDAR D, Houke H, Chiang J, Yi Z, et al
    Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Neuro Oncol. 2020 Dec 15. pii: 6035165. doi: 10.1093.
    PubMed     Abstract available


  459. XIE R, Kessler T, Grosch J, Hai L, et al
    Tumor cell network integration in glioma represents a stemness feature.
    Neuro Oncol. 2020 Dec 15. pii: 6035154. doi: 10.1093.
    PubMed     Abstract available


  460. PUDUVALLI VK
    Demystifying Demethylator Sensitivity in Gliomas: Role for TERT and DNMT1.
    Neuro Oncol. 2020 Dec 2. pii: 6017324. doi: 10.1093.
    PubMed    


  461. HUANG J, Mehta M
    Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
    Neuro Oncol. 2020 Dec 2. pii: 6017294. doi: 10.1093.
    PubMed    


  462. GENOVESI LA, Puttick S, Millar A, Kojic M, et al
    Patient derived orthotopic xenograft models of Medulloblastoma lack a functional blood brain barrier.
    Neuro Oncol. 2020 Dec 1. pii: 6015057. doi: 10.1093.
    PubMed     Abstract available


  463. YUAN M, White D, Resar L, Bar E, et al
    Conditional reprograming culture conditions facilitate growth of lower grade glioma models.
    Neuro Oncol. 2020 Dec 1. pii: 6015051. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  464. KHASRAW M, Walsh KM, Heimberger AB, Ashley DM, et al
    What is the Burden of Proof for Tumor Mutational Burden in gliomas?
    Neuro Oncol. 2020 Nov 30. pii: 6012765. doi: 10.1093.
    PubMed     Abstract available


  465. LARA-VELAZQUEZ M, Zarco N, Carrano A, Phillipps J, et al
    Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.
    Neuro Oncol. 2020 Nov 29. pii: 6010432. doi: 10.1093.
    PubMed     Abstract available


  466. ZHENG ZQ, Chen JT, Zheng MC, Yang LJ, et al
    Nestin +/CD31 + Cells in the Hypoxic Perivascular Niche Regulate Glioblastoma Chemoresistance by Upregulating JAG1 and DLL4.
    Neuro Oncol. 2020 Nov 29. pii: 6010441. doi: 10.1093.
    PubMed     Abstract available


  467. NIU X, Yang Y, Zhou X, Zhang H, et al
    A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.
    Neuro Oncol. 2020 Nov 27. pii: 6007003. doi: 10.1093.
    PubMed    


  468. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Response to Letter to Editor.
    Neuro Oncol. 2020;22:1706-1707.
    PubMed    


  469. LE RHUN E, Weller M, Le Deley MC
    DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?
    Neuro Oncol. 2020;22:1710-1711.
    PubMed    


  470. VOGELBAUM MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al
    Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
    Neuro Oncol. 2020;22:1568-1579.
    PubMed     Abstract available


  471. OERMANN EK, Germano IM
    In the pursuit of glioma diagnosis - the challenges and opportunities of deep neural network augmented analyses.
    Neuro Oncol. 2020 Nov 12. pii: 5979500. doi: 10.1093.
    PubMed    


  472. ALBERT TK, Interlandi M, Sill M, Graf M, et al
    An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.
    Neuro Oncol. 2020 Nov 11. pii: 5974128. doi: 10.1093.
    PubMed     Abstract available


  473. MITCHELL K, Troike K, Silver DJ, Lathia JD, et al
    The evolution of the cancer stem cell state in glioblastoma - emerging insights into the next-generation of functional interactions.
    Neuro Oncol. 2020 Nov 11. pii: 5973946. doi: 10.1093.
    PubMed     Abstract available


  474. BERZERO G, Di Stefano AL, Ronchi S, Bielle F, et al
    IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2020 Nov 11. pii: 5973947. doi: 10.1093.
    PubMed     Abstract available


  475. GRAMATZKI D, Felsberg J, Roth P, Kaulich K, et al
    The molecular evolution of glioblastoma treated by gross total resection alone.
    Neuro Oncol. 2020 Nov 11. pii: 5973944. doi: 10.1093.
    PubMed    


  476. SAHEBJAM S, Forsyth PA, Tran ND, Arrington JA, et al
    Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
    Neuro Oncol. 2020 Nov 11. pii: 5973945. doi: 10.1093.
    PubMed     Abstract available


  477. YI K, Zhan Q, Wang Q, Tan Y, et al
    PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
    Neuro Oncol. 2020 Nov 3. pii: 5952479. doi: 10.1093.
    PubMed     Abstract available


  478. VITANZA NA, Biery MC, Myers C, Ferguson E, et al
    Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models.
    Neuro Oncol. 2020 Nov 1. pii: 5948533. doi: 10.1093.
    PubMed     Abstract available


  479. MANJUNATH M, Yan J, Youn Y, Drucker KL, et al
    Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
    Neuro Oncol. 2020 Nov 1. pii: 5948532. doi: 10.1093.
    PubMed     Abstract available


  480. DEJAEGHER J, Solie L, Hunin Z, Sciot R, et al
    DNA Methylation based glioblastoma subclassification is related to tumoral T cell infiltration and patient survival.
    Neuro Oncol. 2020 Nov 1. pii: 5948531. doi: 10.1093.
    PubMed     Abstract available


  481. KLEIN M, Drijver AJ, van den Bent MJ, Bromberg JC, et al
    Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.
    Neuro Oncol. 2020 Nov 1. pii: 5948535. doi: 10.1093.
    PubMed     Abstract available


  482. SIEVERS P, Sill M, Schrimpf D, Stichel D, et al
    A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
    Neuro Oncol. 2020 Nov 1. pii: 5948536. doi: 10.1093.
    PubMed     Abstract available


  483. JI SY, Lee J, Lee JH, Lee ST, et al
    Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.
    Neuro Oncol. 2020 Nov 1. pii: 5948534. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  484. OSTROM QT, Patil N, Cioffi G, Waite K, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
    Neuro Oncol. 2020;22.
    PubMed     Abstract available


  485. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2020 Oct 28. pii: 5942594. doi: 10.1093.
    PubMed    


  486. CICONE F, Carideo L, Scaringi C, Romano A, et al
    Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
    Neuro Oncol. 2020 Oct 23. pii: 5936979. doi: 10.1093.
    PubMed     Abstract available


  487. MYNAREK M, Rutkowski S
    Young children with medulloblastoma: Important open questions and the high-risk dilemma.
    Neuro Oncol. 2020 Oct 23. pii: 5936023. doi: 10.1093.
    PubMed    


  488. GONDI V, Mehta MP
    Radiotherapy Innovations to Optimize Brain Metastases Control.
    Neuro Oncol. 2020 Oct 22. pii: 5934824. doi: 10.1093.
    PubMed    


  489. BROSSIER NM, Thondapu S, Cobb OM, Dahiya S, et al
    Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma.
    Neuro Oncol. 2020 Oct 20. pii: 5932401. doi: 10.1093.
    PubMed     Abstract available


  490. CHO SJ, Sunwoo L, Baik SH, Bae YJ, et al
    Brain Metastasis Detection using Machine Learning: A Systematic Review and Meta-analysis.
    Neuro Oncol. 2020 Oct 19. pii: 5930826. doi: 10.1093.
    PubMed     Abstract available


  491. GROSSMAN SA
    The Duration of Adjuvant Temozolomide in Patients with Glioblastoma and the Law of Diminishing Returns.
    Neuro Oncol. 2020 Oct 19. pii: 5930402. doi: 10.1093.
    PubMed    


  492. SKINNER KR, Nabors LB, Miller CR
    Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
    Neuro Oncol. 2020 Oct 19. pii: 5930390. doi: 10.1093.
    PubMed    


  493. ZHUANG H, Wang Y, Cheng C, Shi S, et al
    The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy.
    Neuro Oncol. 2020 Oct 19. pii: 5930379. doi: 10.1093.
    PubMed    


  494. YOUNGBLOOD MW, Miyagishima DF, Jin L, Gupte T, et al
    Associations of Meningioma Molecular Subgroup and Tumor Recurrence.
    Neuro Oncol. 2020 Oct 17. pii: 5928913. doi: 10.1093.
    PubMed     Abstract available


  495. LAMBA N, Kearney RB, Catalano PJ, Hassett MJ, et al
    Population-based estimates of survival among elderly patients with brain metastases.
    Neuro Oncol. 2020 Oct 17. pii: 5929216. doi: 10.1093.
    PubMed     Abstract available


  496. BEIG N, Singh S, Bera K, Prasanna P, et al
    Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in Glioblastoma.
    Neuro Oncol. 2020 Oct 17. pii: 5929182. doi: 10.1093.
    PubMed     Abstract available


  497. BINDRA RS
    Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
    Neuro Oncol. 2020 Oct 16. pii: 5924496. doi: 10.1093.
    PubMed    


  498. OPITZ CA, Turcan S
    From anti-aging drugs to cancer therapy: Is there a potential for sirtuin activators in gliomas?
    Neuro Oncol. 2020 Oct 16. pii: 5924499. doi: 10.1093.
    PubMed    


  499. ALNAHHAS I, Rayi A, Ong S, Giglio P, et al
    Management of gliomas in patients with Lynch Syndrome.
    Neuro Oncol. 2020 Oct 16. pii: 5924485. doi: 10.1093.
    PubMed    


  500. CHAMBERLAIN MC
    Leptomeningeal metastases: how best to assess response.
    Neuro Oncol. 2020;22:1417-1418.
    PubMed    


  501. ROSSI M, Gay L, Ambrogi F, Nibali MC, et al
    Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas.
    Neuro Oncol. 2020 Oct 13. pii: 5922564. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  502. DAS S
    The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
    Neuro Oncol. 2020;22:1399.
    PubMed    


  503. XU W, Hu X, Zhang J
    Letter regarding article "Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion".
    Neuro Oncol. 2020;22:1400-1401.
    PubMed    


  504. KOTECHA R, Yomo S, Suh JH
    Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion".
    Neuro Oncol. 2020;22:1402-1403.
    PubMed    


  505. TSANG DS, Kim L, Liu ZA, Janzen L, et al
    Intellectual changes after radiation for children with brain tumors: which brain structures are most important?
    Neuro Oncol. 2020 Sep 16. pii: 5906521. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  506. GUERREIRO STUCKLIN AS, Mueller S
    Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
    Neuro Oncol. 2020 Aug 25. pii: 5896906. doi: 10.1093.
    PubMed    


  507. BOHM AK, DePetro J, Binding CE, Gerber A, et al
    In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
    Neuro Oncol. 2020;22:1150-1161.
    PubMed     Abstract available


  508. SHI C, Ye Z, Han J, Ye X, et al
    BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
    Neuro Oncol. 2020;22:1114-1125.
    PubMed     Abstract available


  509. WICK A, Kessler T, Platten M, Meisner C, et al
    Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Neuro Oncol. 2020;22:1162-1172.
    PubMed     Abstract available


    July 2020
  510. KARREMAN MA, Winkler F
    Targeting an adhesion molecule to prevent brain colonization of lung cancer.
    Neuro Oncol. 2020;22:899-900.
    PubMed    


  511. GEURTS M, van den Bent MJ
    Fast-growing oligodendrogliomas are aggressive tumors-the real life biomarker?
    Neuro Oncol. 2020;22:907-908.
    PubMed    


  512. COLO F, Larrouquere L, Rivoirard R, Loiseau H, et al
    Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults.
    Neuro Oncol. 2020;22:1046-1047.
    PubMed    


  513. JAIN R, Johnson DR, Patel SH, Castillo M, et al
    "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Neuro Oncol. 2020;22:936-943.
    PubMed     Abstract available


  514. ROUX A, Tauziede-Espariat A, Zanello M, Peeters S, et al
    Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Neuro Oncol. 2020;22:993-1005.
    PubMed     Abstract available


    June 2020
  515. BENNETT J, Bouffet E
    Neuro-oncology in adolescents and young adults-an unmet need.
    Neuro Oncol. 2020;22:752-753.
    PubMed    


  516. HU LS, Swanson KR
    Roadmap for the clinical integration of radiomics in neuro-oncology.
    Neuro Oncol. 2020;22:743-745.
    PubMed    


    March 2020
  517. KOTECHA R, Sahgal A, Rubens M, De Salles A, et al
    Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
    Neuro Oncol. 2020;22:318-332.
    PubMed     Abstract available


  518. LASOCKI A, Khoo C, Lau PKH, Kok DL, et al
    High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
    Neuro Oncol. 2020;22:423-432.
    PubMed     Abstract available


    February 2020
  519. OSTROM QT, Kruchko C, Barnholtz-Sloan JS
    Pilocytic astrocytomas: where do they belong in cancer reporting?
    Neuro Oncol. 2020;22:298-300.
    PubMed    


    January 2020
  520. TEW BY, Legendre C, Schroeder MA, Triche T, et al
    Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
    Neuro Oncol. 2020;22:70-83.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: